{"content":"<li class=\"n-box-item date-title\" data-end=\"1559620799\" data-start=\"1559534400\" data-txt=\"Monday, December 23, 2019\">Monday, June  3, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3468765\" data-ts=\"1559597343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468765-revg-nav-box-and-amt-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">REVG, NAV, BOX and AMT among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/WMWXF' title='DEUT BK ELNTS LKD MRGSTAR'>OTCPK:WMWXF</a> <font color=\"green\">+15.9%</font>. <a href='https://seekingalpha.com/symbol/TLLYF' title='Trilogy International Partners Inc.'>OTC:TLLYF</a> <font color=\"green\">+7.6%</font>. <a href='https://seekingalpha.com/symbol/REVG' title='REV Group, Inc.'>REVG</a> <font color=\"green\">+5.0%</font>. <a href='https://seekingalpha.com/symbol/PVTL' title='Pivotal Software, Inc.'>PVTL</a> <font color=\"green\">+4.6%</font>. <a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color=\"green\">+4.4%</font>.</li><li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/AMT' title='American Tower Corporation &#40;REIT&#41;'>AMT</a> <font color=\"red\">-14.5%</font>. <a href='https://seekingalpha.com/symbol/BOX' title='Box, Inc.'>BOX</a> <font color=\"red\">-10.7%</font>. <a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a> <font color=\"red\">-7.9%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a> <font color=\"red\">-7.7%</font>. <a href='https://seekingalpha.com/symbol/MTDR' title='Matador Resources Company'>MTDR</a> <font color=\"red\">-4.0%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468765\" data-linked=\"REVG, NAV, BOX and AMT among after hour movers\" data-tweet=\"$WMWXF $TLLYF $REVG - REVG, NAV, BOX and AMT among after hour movers https://seekingalpha.com/news/3468765-revg-nav-box-and-amt-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3468765-revg-nav-box-and-amt-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468700\" data-ts=\"1559594675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADRO\" target=\"_blank\">ADRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468700-aduro-down-42-on-underwhelming-data-on-sting-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aduro down 42% on underwhelming data on STING candidate</a></h4><ul><li>Aduro Biotech (<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a> <font color=\"red\">-42.2%</font>) slumps on a 4x surge in volume in response to <a href=\"https://seekingalpha.com/pr/17531054-aduro-biotech-novartis-present-results-ongoing-phase-1b-study-sting-agonist-adu-s100-miw815\" target=\"_blank\">data</a> presented at ASCO on STING candidate ADU-S100.</li><li>Investors are clearly disappointed with interim results from a Phase 1b clinical trial evaluating the combination of ADU-S100 and collaboration partner Novartis' (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"green\">+2.4%</font>) investigational PD-1 inhibitor spartalizumab in patients with solid tumors or lymphomas.</li><li>The data are based on 83 patients, 53 who received weekly IV doses of ADU-S100 and 30 who received monthly doses (spartalizumab was administered on day 1).</li><li>In the weekly group, there were five responders, three with triple-negative breast cancer (n=3/11) and two with melanoma. Eight TNBC patients were evaluable implying a response rate of 38% (n=3/8). 25 of 35 melanoma patients were evaluable. Nine achieved stable cancer implying a disease control rate of 44% (n=11/25).</li><li>In the monthly group, only six patients achieved stable cancer.</li><li>Investors are still waiting for STING data that they can get excited about.</li><li>Related tickers: Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>), Takeda (NYSE:<a href='https://seekingalpha.com/symbol/TAK' title='Takeda Pharmaceutical Company Limited'>TAK</a>), Trillium Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIL' title='Trillium Therapeutics Inc.'>TRIL</a>), Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a>), Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>)</li><li>#ASCO19</li></ul><div class=\"tiny-share-widget\" data-id=\"3468700\" data-linked=\"Aduro down 42% on underwhelming data on STING candidate\" data-tweet=\"$ADRO $NVS $SYBX - Aduro down 42% on underwhelming data on STING candidate https://seekingalpha.com/news/3468700-aduro-down-42-on-underwhelming-data-on-sting-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3468700-aduro-down-42-on-underwhelming-data-on-sting-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468745\" data-ts=\"1559594566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APPS\" target=\"_blank\">APPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468745-digital-turbineplus-2_2-after-q4-revenues-grow-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Turbine +2.2% after Q4 revenues grow 30%</a></h4><ul>   <li>Digital Turbine (NASDAQ:<a href='https://seekingalpha.com/symbol/APPS' title='Digital Turbine, Inc.'>APPS</a>) is <font color=\"green\">up 2.2%</font> after hours following a beat on top and bottom lines with its fiscal Q4 earnings report.</li>    <li>Revenues grew 30% to $27.2M, driven by strong revenue per device with U.S. partners.</li>    <li>Adjusted EBITDA surpassed $3M despite slower smartphone sales in the U.S. for the quarter.</li>    <li>GAAP net loss widened to $6.8M from $4.2M; meanwhile, non-GAAP adjusted net income increased to $2.4M vs. a prior loss of $0.6M.</li>    <li>Non-GAAP free cash flow was $1.9M.</li>    <li>It's guiding to Q1 revenue of $28M-$28.5M and EBITDA of $2.2M-$2.6M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3468721-digital-turbine-eps-beats-0_01-beats-revenue\" target=\"_blank\">Digital Turbine EPS beats by $0.01, beats on revenue</a> (Jun. 03 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17532567-digital-turbine-reports-fourth-quarter-fiscal-full-year-2019-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3468745\" data-linked=\"Digital Turbine +2.2% after Q4 revenues grow 30%\" data-tweet=\"$APPS - Digital Turbine +2.2% after Q4 revenues grow 30% https://seekingalpha.com/news/3468745-digital-turbineplus-2_2-after-q4-revenues-grow-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3468745-digital-turbineplus-2_2-after-q4-revenues-grow-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468743\" data-ts=\"1559594428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468743-coupaplus-4_2-on-upside-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa +4.2% on upside revenue guidance</a></h4><ul><li>Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Incorporated'>COUP</a>) <font color=\"green\">gains 4.2%</font> on <a href=\"https://seekingalpha.com/news/3468711-coupa-software-eps-beats-0_07-beats-revenue\" target=\"_blank\">Q1 beats </a>with 44% Y/Y revenue growth.</li><li>The Q2 outlook has upside revenue from $84.5-85.5M (estimate: $78.07M) and downside loss per share of $0.12 to $0.1 (estimate: $0.01 loss).</li><li>FY20 guidance has upside revenue $342-$344M (estimate: $327.97M) and in-line EPS of $0.07 to $0.10 (estimate: $0.08).</li><li>Revenue breakdown: Subscription service, $73.0M (consensus: $67.7M); Professional services, $8.4M (consensus: $6.1M).</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=2484981-1&amp;h=2475201002&amp;u=http%3A%2F%2Finvestors.coupa.com%2F&amp;a=http%3A%2F%2Finvestors.coupa.com\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17532518-coupa-software-reports-financial-results-first-quarter-fiscal-2020\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468743\" data-linked=\"Coupa +4.2% on upside revenue guidance\" data-tweet=\"$COUP - Coupa +4.2% on upside revenue guidance https://seekingalpha.com/news/3468743-coupaplus-4_2-on-upside-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3468743-coupaplus-4_2-on-upside-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468742\" data-ts=\"1559594420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTR\" target=\"_blank\">VTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468742-ventas-to-buy-seniors-housing-portfolio-valued-1_8b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ventas to buy seniors housing portfolio valued at $1.8B</a></h4><ul><li>Ventas (NYSE:<a href='https://seekingalpha.com/symbol/VTR' title='Ventas, Inc.'>VTR</a>) <a href=\"https://seekingalpha.com/pr/17532515-ventas-acquire-high-quality-canadian-seniors-housing-portfolio-partnership-le-groupe-maurice\" target=\"_blank\">agrees to buy</a> a portfolio of 31 seniors housing communities and four in-progress developments in the Quebec market by investing in an 85%/15% equity partnership with Le Groupe Maurice.</li><li>Portfolio is valued at C$2.4B (US$1.8B), including construction in progress.</li><li>Ventas <font color=\"red\">falls 1.7%</font> in after-hours trading.</li><li>Ventas secured exclusive rights to own and fund all LGM future developments under a pipeline agreement, which should provide long-term sustainable growth; new incremental developments are expected to average two to three new starts per year.</li><li>Sees deal neutral to 2019 normalized FFO per share and accretive to 2020 normalized FFO by ~3 cents per share.</li><li>Sees LGM deal closing in two phases, with the first expected to close early in Q3 and the second in late Q3 2019.</li><li>P<a href=\"https://seekingalpha.com/pr/17532547-ventas-announces-public-offering-common-stock\" target=\"_blank\">lans to sell </a>up to 11M shares of common stock in a public offering.</li><li>Intends to grant greenshoe option for an additional 1.65M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468742\" data-linked=\"Ventas to buy seniors housing portfolio valued at $1.8B\" data-tweet=\"$VTR - Ventas to buy seniors housing portfolio valued at $1.8B https://seekingalpha.com/news/3468742-ventas-to-buy-seniors-housing-portfolio-valued-1_8b?source=tweet\" data-url=\"https://seekingalpha.com/news/3468742-ventas-to-buy-seniors-housing-portfolio-valued-1_8b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468727\" data-ts=\"1559593501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOX\" target=\"_blank\">BOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468727-boxminus-8-on-downside-revenue-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Box -8% on downside revenue outlook</a></h4><ul><li>Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box, Inc.'>BOX</a>) <font color=\"red\">falls 8.4%</font> after <a href=\"https://seekingalpha.com/news/3468708-box-eps-beats-0_02-beats-revenue\" target=\"_blank\">Q1 results</a> beat estimates but the FY20 outlook was mixed.</li><li>Q2 guidance has downside revenue of $169-170M (estimate: $170.89M) and in-line loss per share of $0.02 to $0.01 (estimate: $0.02 loss).</li><li>FY20 has downside revenue of $688-692M (estimate: $702.06M) and upside EPS of $0 to $0.02 (estimate: $0.02 loss).</li><li>Q1 cash from operations totaled $25.5M and FCF was $17.6M.</li><li>Non-GAAP operating margin was -2% versus the -4.7%.</li><li>Earnings call starts at 5 PM ET with a webcast<a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.box.com%2Finvestors&amp;esheet=51993278&amp;newsitemid=20190603005742&amp;lan=en-US&amp;anchor=www.box.com%2Finvestors&amp;index=10&amp;md5=5e42554f42527e9b7973e9b630dc09a5\" target=\"_blank\"> here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17532530-box-reports-revenue-163_0-million-fiscal-first-quarter-2020-16-percent-year-year\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468727\" data-linked=\"Box -8% on downside revenue outlook\" data-tweet=\"$BOX - Box -8% on downside revenue outlook https://seekingalpha.com/news/3468727-boxminus-8-on-downside-revenue-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3468727-boxminus-8-on-downside-revenue-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468725\" data-ts=\"1559593277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEN\" target=\"_blank\">SIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468725-sientra-commences-secondary-public-offering-of-75m-shares-slide-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sientra commences secondary public offering of $75M; shares slide ~10%</a></h4><ul><li>Sientra (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a>) is down <font color=\"red\">9.6%</font> as the company <a href=\"https://seekingalpha.com/pr/17532511-sientra-commences-public-offering-common-stock\" target=\"_blank\">commenced</a> an underwritten public follow-on offering of ~$75M of its common stock</li><li>Underwriters have an option to purchase up to $11.25M of additional shares.</li><li><p>Sientra intends to use the net proceeds to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes.</p></li></ul><div class=\"tiny-share-widget\" data-id=\"3468725\" data-linked=\"Sientra commences secondary public offering of $75M; shares slide ~10%\" data-tweet=\"$SIEN - Sientra commences secondary public offering of $75M; shares slide ~10% https://seekingalpha.com/news/3468725-sientra-commences-secondary-public-offering-of-75m-shares-slide-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3468725-sientra-commences-secondary-public-offering-of-75m-shares-slide-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468720\" data-ts=\"1559593059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAL\" target=\"_blank\">CAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468720-caleres-tops-q1-mark-lowers-full-year-profit-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caleres tops Q1 mark, lowers full-year profit outlook</a></h4><ul><li>Caleres (NYSE:<a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a>) reports comparable sales at Famous Footwear stores fell 1% in <a href=\"https://seekingalpha.com/pr/17532550-caleres-reports-first-quarter-2019-results\" target=\"_blank\">Q1</a> vs. -0.3% consensus.</li><li>Gross profit at Famous Footwear fell 210 bps to 43.4% of sales.</li><li>CEO update: \"Despite a soft marketplace, Brand Portfolio performed extremely well and continued to grow \u2013 with sales up more than 20% year-over-year \u2013 and to take share. Once again, we owned six of the top 25 women's fashion footwear brands and grew sales ahead of market rate while gaining share.\"</li><li>Looking ahead, Caleres expects FY19 sales of $3.0B and EPS of $2.35 to $2.45 vs. $2.45 to $2.55 prior and $2.48 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3468713-caleres-eps-beats-0_01-beats-revenue\" target=\"_blank\">Caleres EPS beats by $0.01, beats on revenue</a> (June 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3468720\" data-linked=\"Caleres tops Q1 mark, lowers full-year profit outlook\" data-tweet=\"$CAL - Caleres tops Q1 mark, lowers full-year profit outlook https://seekingalpha.com/news/3468720-caleres-tops-q1-mark-lowers-full-year-profit-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3468720-caleres-tops-q1-mark-lowers-full-year-profit-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468719\" data-ts=\"1559593044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468719-rate-hopes-annaly-buyback-boost-mreits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rate hopes, Annaly buyback boost mREITs</a></h4><ul><li>It's been a wave of capital raising for the mREITs in 2019, but Annaly Capital (<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> <font color=\"green\">+2.8%</font>) this morning perhaps launched a wave of capital returns with <a href=\"https://seekingalpha.com/news/3468509-annaly-capital-plus-1_7-percent-1_5b-stock-buyback-program\" target=\"_blank\">a $1.5B buyback announcement</a>.</li><li>Then this afternoon, hopes were raised for a return to a positively sloping yield curve after St. Louis Fed President Jim Bullard <a href=\"https://seekingalpha.com/news/3468688-feds-bullard-sounds-ready-rate-cut\" target=\"_blank\">said conditions may already</a> be in place for a rate cut.</li><li>AGNC Investment (<a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color=\"green\">+2.2%</font>), Chimera (<a href='https://seekingalpha.com/symbol/CIM' title='Chimera Investment Corporation'>CIM</a> <font color=\"green\">+2.1%</font>), Two Harbors (<a href='https://seekingalpha.com/symbol/TWO' title='Two Harbors Investment Corp.'>TWO</a> <font color=\"green\">+1.6%</font>), Armour (<a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a> <font color=\"green\">+3.4%</font>), Orchid Island (<a href='https://seekingalpha.com/symbol/ORC' title='Orchid Island Capital, Inc.'>ORC</a> <font color=\"green\">+2%</font>), New York Mortgage (<a href='https://seekingalpha.com/symbol/NYMT' title='New York Mortgage Trust, Inc.'>NYMT</a> <font color=\"green\">+1.7%</font>), Western Asset (<a href='https://seekingalpha.com/symbol/WMC' title='Western Asset Mortgage Capital Corporation'>WMC</a> <font color=\"green\">+1.1%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3468719\" data-linked=\"Rate hopes, Annaly buyback boost mREITs\" data-tweet=\"$NLY $AGNC $CIM - Rate hopes, Annaly buyback boost mREITs https://seekingalpha.com/news/3468719-rate-hopes-annaly-buyback-boost-mreits?source=tweet\" data-url=\"https://seekingalpha.com/news/3468719-rate-hopes-annaly-buyback-boost-mreits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468701\" data-ts=\"1559591830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468701-internal-changes-blamed-for-fedex-misrouted-packages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Internal changes blamed for FedEx misrouted packages</a></h4><ul><li>Sources indicate that FedEx (<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color='red'>-1.4%</font>) mistakenly routing two Huawei Technologies packages to the U.S. were due to <a href=\"https://www.wsj.com/articles/fedex-misrouted-huawei-packages-after-changes-to-internal-protocols-11559589898?mod=djemalertNEWS\" target=\"_blank\">changes</a> in its system made to comply with the Trump administration's crackdown on the Chinese company.</li><li>While Huawei accused FedEx of diverting two packages from Japan and attempting to divert two from Vietnam, the company says the actions were unintentional.</li><li>Shares of FDX have pared their loss from the beginning of the day.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468701\" data-linked=\"Internal changes blamed for FedEx misrouted packages\" data-tweet=\"$FDX - Internal changes blamed for FedEx misrouted packages https://seekingalpha.com/news/3468701-internal-changes-blamed-for-fedex-misrouted-packages?source=tweet\" data-url=\"https://seekingalpha.com/news/3468701-internal-changes-blamed-for-fedex-misrouted-packages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468696\" data-ts=\"1559590325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468696-boeing-ceo-sees-max-jets-back-in-air-years-end-offers-no-timeline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing CEO sees MAX jets back in the air by year&#39;s end but offers no timeline</a></h4><ul><li>Boeing's (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"red\">-1.7%</font>) 737 MAX jets likely will get the green light to fly again by the end of this year, CEO Dennis Muilenburg tells CNBC, while declining to provide a specific timetable.</li><li>The company is conducting simulated flights with air safety regulators this week and expects to fly the MAX with the Federal Aviation Administration \"very soon\" afterward to get the grounded plane cleared to return to service, the CEO says.</li><li>Boeing will work closely with customers to repair \"damaged trust\" of the flying public but this \"will take time,\" Muilenberg says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468696\" data-linked=\"Boeing CEO sees MAX jets back in the air by year&#39;s end but offers no timeline\" data-tweet=\"$BA - Boeing CEO sees MAX jets back in the air by year&#39;s end but offers no timeline https://seekingalpha.com/news/3468696-boeing-ceo-sees-max-jets-back-in-air-years-end-offers-no-timeline?source=tweet\" data-url=\"https://seekingalpha.com/news/3468696-boeing-ceo-sees-max-jets-back-in-air-years-end-offers-no-timeline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>133&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468695\" data-ts=\"1559590214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXRH\" target=\"_blank\">TXRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468695-buybacks-on-menu-texas-roadhouse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buybacks on the menu at Texas Roadhouse</a></h4><ul><li>Texas Roadhouse (<a href='https://seekingalpha.com/symbol/TXRH' title='Texas Roadhouse, Inc.'>TXRH</a> <font color='green'>+4.3%</font>) rallies after the board approved a new $250M share repurchase plan.</li><li>Shares of TXRH are trading at their session high.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468695\" data-linked=\"Buybacks on the menu at Texas Roadhouse\" data-tweet=\"$TXRH - Buybacks on the menu at Texas Roadhouse https://seekingalpha.com/news/3468695-buybacks-on-menu-texas-roadhouse?source=tweet\" data-url=\"https://seekingalpha.com/news/3468695-buybacks-on-menu-texas-roadhouse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468682\" data-ts=\"1559589461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468682-clovis-up-1-on-new-rubraca-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis  up 1% on new Rubraca data</a></h4><ul><li>Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a> <font color=\"green\">+1.2%</font>) is up on below-average volume on the heels of <a href=\"https://seekingalpha.com/pr/17530976-expanded-rubraca-rucaparib-data-clovis-oncology-s-ariel3-triton2-trials-ovarian-prostate\" target=\"_blank\">new Rubraca (rucaparib) dat</a>a that was presented at ASCO in Chicago.</li><li>Updated results from the Phase 3 ARIEL3 trial showed a similar safety profile that was previously reported based on a data cut-off of April 15, 2017. The most common treatment-emergent adverse events (TEAEs) of any grade were nausea (76%), asthenia (physical weakness)/fatigue (71%), dysgeusia (loss of taste sensation) (40%) and anemia/decreased hemoglobin (39%). The most common grade \u22653 (serious/life-threatening) TEAEs were anemia/decreased hemoglobin (22%) and alanine/aspartate aminotransferase increase (biomarkers of liver stress) (10%).</li><li>Updated data from the Phase 2 TRITON2 study assessing Rubraca in patients with metastatic castration-resistant prostate cancer showed an objective response rate &#40;ORR&#41; of 50% (n=5/10) in those with a germline or somatic BRCA1/2 mutation (RECIST/PCWG3 criteria).</li><li>Up-to-date results from TRITON2 will be presented at a medical conference in H2.</li><li>#ASCO19</li></ul><div class=\"tiny-share-widget\" data-id=\"3468682\" data-linked=\"Clovis  up 1% on new Rubraca data\" data-tweet=\"$CLVS - Clovis up 1% on new Rubraca data https://seekingalpha.com/news/3468682-clovis-up-1-on-new-rubraca-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468682-clovis-up-1-on-new-rubraca-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468691\" data-ts=\"1559589451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468691-plunge-in-tech-heavyweights-sends-nasdaq-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plunge in tech heavyweights sends Nasdaq down 2%</a></h4><ul><li>A wave of D.C. scrutiny of the country's tech giants has Facebook and Google <font color=\"red\">down nearly 7%</font>, Amazon <font color=\"red\">5%</font>, and Apple <font color=\"red\">1.5%</font>. That's helping the Nasdaq to a <font color=\"red\">2% loss</font>.</li><li>The S&amp;P 500 is <font color=\"red\">down 0.5%</font> and Dow <font color=\"red\">0.25%</font>.</li><li>The 10-year Treasury yield is off more than six basis points to 2.06%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468691\" data-linked=\"Plunge in tech heavyweights sends Nasdaq down 2%\" data-tweet=\"Plunge in tech heavyweights sends Nasdaq down 2% https://seekingalpha.com/news/3468691-plunge-in-tech-heavyweights-sends-nasdaq-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3468691-plunge-in-tech-heavyweights-sends-nasdaq-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468689\" data-ts=\"1559589142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468689-illinois-gaming-bill-sends-casino-investors-scrambling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Illinois gaming bill sends casino investors scrambling</a></h4><ul><li>The casino sector is volatile after a gambling bill is <a href=\"https://seekingalpha.com/news/3468586-illinois-gaming-hits-hyperspeed\" target=\"_blank\">passed</a> in Illinois.</li><li>MGM Resorts (<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color=\"red\">-3.8%</font>), Eldorado Resorts (<a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a> <font color=\"red\">-5.8%</font>), Boyd Gaming (<a href='https://seekingalpha.com/symbol/BYD' title='Boyd Gaming Corporation'>BYD</a> <font color=\"red\">-4.5%</font>), Full House Resorts (<a href='https://seekingalpha.com/symbol/FLL' title='Full House Resorts, Inc.'>FLL</a> <font color=\"red\">-4%</font>) and Penn National Gaming (<a href='https://seekingalpha.com/symbol/PENN' title='Penn National Gaming, Inc.'>PENN</a> <font color=\"red\">-7.1%</font>) are trading lower on concerns of competition from even more states in the future, while suppliers Scientific Games (<a href='https://seekingalpha.com/symbol/SGMS' title='Scientific Games Corporation'>SGMS</a> <font color=\"green\">+8%</font>) and International Game Technology (<a href='https://seekingalpha.com/symbol/IGT' title='International Game Technology PLC'>IGT</a> <font color=\"green\">+3.1%</font>) are notably higher.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468689\" data-linked=\"Illinois gaming bill sends casino investors scrambling\" data-tweet=\"$MGM $ERI $BYD - Illinois gaming bill sends casino investors scrambling https://seekingalpha.com/news/3468689-illinois-gaming-bill-sends-casino-investors-scrambling?source=tweet\" data-url=\"https://seekingalpha.com/news/3468689-illinois-gaming-bill-sends-casino-investors-scrambling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468687\" data-ts=\"1559588413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468687-cypress-semiconductor-leads-tech-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cypress Semiconductor leads tech gainers</a></h4><ul><li><strong>Gainers: </strong>Cypress Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>) <font color=\"green\">+24%</font>. Daqo New Energy (NYSE:<a href='https://seekingalpha.com/symbol/DQ' title='Daqo New Energy Corp.'>DQ</a>) <font color=\"green\">+13%</font>. Resonant (NASDAQ:<a href='https://seekingalpha.com/symbol/RESN' title='Resonant Inc.'>RESN</a>) <font color=\"green\">+13%</font>. Sigma Labs (NASDAQ:<a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a>) <font color=\"green\">+11%</font>. Atomera Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Incorporated'>ATOM</a>) <font color=\"green\">+10%</font>.</li> <li><strong>Losers: </strong>Mesa Laboratories (NASDAQ:<a href='https://seekingalpha.com/symbol/MLAB' title='Mesa Laboratories, Inc.'>MLAB</a>) <font color=\"red\">-26%</font>. Support.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SPRT' title='Support.com, Inc.'>SPRT</a>) <font color=\"red\">-22%</font>. Pintec Technology Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PT' title='Pintec Technology Holdings Limited'>PT</a>) <font color=\"red\">-21%</font>. TrueCar (NASDAQ:<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc.'>TRUE</a>) <font color=\"red\">-18%</font>. Eltek (NASDAQ:<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a>) <font color=\"red\">-15%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3468687\" data-linked=\"Cypress Semiconductor leads tech gainers\" data-tweet=\"$CY $DQ $RESN - Cypress Semiconductor leads tech gainers https://seekingalpha.com/news/3468687-cypress-semiconductor-leads-tech-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3468687-cypress-semiconductor-leads-tech-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468683\" data-ts=\"1559584818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468683-alexco-resource-and-centrus-energy-among-energy-materials-gainers-westwater-resources-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexco Resource and Centrus Energy among Energy/Materials gainers; Westwater Resources and Covia among losers</a></h4><ul><li><b>Gainers: </b>Alexco Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corp.'>AXU</a>) <font color=\"green\">+12%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"green\">+12%</font>. Eldorado Gold (NYSE:<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a>) <font color=\"green\">+11%</font>. Hecla Mining (NYSE:<a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Company'>HL</a>) <font color=\"green\">+11%</font>. DRDGOLD (NYSE:<a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a>) <font color=\"green\">+11%</font>.</li><li><b>Losers: </b>Westwater Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/WWR' title='Westwater Resources, Inc.'>WWR</a>) <font color=\"red\">-11%</font>. Covia (NYSE:<a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a>) <font color=\"red\">-9%</font>. Independence Contract Drilling (NYSE:<a href='https://seekingalpha.com/symbol/ICD' title='Independence Contract Drilling, Inc.'>ICD</a>) <font color=\"red\">-9%</font>. Ossen Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a>) <font color=\"red\">-8%</font>. NCS Multistage (NASDAQ:<a href='https://seekingalpha.com/symbol/NCSM' title='NCS Multistage Holdings, Inc.'>NCSM</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468683\" data-linked=\"Alexco Resource and Centrus Energy among Energy/Materials gainers; Westwater Resources and Covia among losers\" data-tweet=\"$AXU $LEU $EGO - Alexco Resource and Centrus Energy among Energy/Materials gainers; Westwater Resources and Covia among losers https://seekingalpha.com/news/3468683-alexco-resource-and-centrus-energy-among-energy-materials-gainers-westwater-resources-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3468683-alexco-resource-and-centrus-energy-among-energy-materials-gainers-westwater-resources-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468678\" data-ts=\"1559583673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468678-doj-heading-apple-antitrust-probe-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DoJ heading Apple antitrust probe - Reuters</a></h4><ul><li>Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>)<font color=\"red\"> drops 2%</font> on a <a href=\"https://www.reuters.com/article/us-apple-stocks/apple-dips-on-news-of-doj-antitrust-probe-idUSKCN1T42IJ?feedType=RSS&amp;feedName=businessNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FbusinessNews+%28Business+News%29\" target=\"_blank\">Reuters report</a> that the U.S. Department of Justice will receive jurisdiction over a potential antitrust probe.</li><li>The DoJ and FTC recently held meetings to determine who would oversee broad investigations into the tech industry.</li><li>Last week, Bloomberg <a href=\"https://seekingalpha.com/news/3468635-ftc-lead-facebook-probes-doj-lead-google\" target=\"_blank\">reported </a>a similar DoJ arrangement for a Google probe.</li><li>Post updated to include source link.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468678\" data-linked=\"DoJ heading Apple antitrust probe - Reuters\" data-tweet=\"$AAPL - DoJ heading Apple antitrust probe - Reuters https://seekingalpha.com/news/3468678-doj-heading-apple-antitrust-probe-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3468678-doj-heading-apple-antitrust-probe-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>99&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468677\" data-ts=\"1559583343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POAHY\" target=\"_blank\">POAHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468677-porsche-u-s-retail-sales-rose-0_1-in-may\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Porsche U.S. retail sales rose 0.1% in May</a></h4><ul><li>Porsche (<a href='https://seekingalpha.com/symbol/POAHY' title='Porsche Automobil Holding SE'>OTCPK:POAHY</a>) unit sales rose <a href=\"https://seekingalpha.com/pr/17532222-porsche-reports-may-u-s-retail-sales\" sasource=\"qp_sum_news_1\" target=\"_blank\">0.1%</a> to 5,010 units in March.</li><li>911 sales declined 23.5% to 613 units.</li><li>718 sales dropped 14.1% to 456 units</li><li>Cayenne sales soared 213.4% to 1,680 units.</li><li>Panamera sales decreased 41.9% to 521 units.</li><li>Macan sales fell 22.4% to 1,740 units.</li><li>YTD Porsche U.S. sales +2.1% to 25,052 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468677\" data-linked=\"Porsche U.S. retail sales rose 0.1% in May\" data-tweet=\"$POAHY $POAHF - Porsche U.S. retail sales rose 0.1% in May https://seekingalpha.com/news/3468677-porsche-u-s-retail-sales-rose-0_1-in-may?source=tweet\" data-url=\"https://seekingalpha.com/news/3468677-porsche-u-s-retail-sales-rose-0_1-in-may\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468674\" data-ts=\"1559582768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HYMLF\" target=\"_blank\">HYMLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468674-hyundai-may-u-s-sales-rose-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hyundai May U.S. sales rose 2%</a></h4><ul> <li>Hyundai (<a href='https://seekingalpha.com/symbol/HYMLF' title='Hyundai Motor Company'>OTCPK:HYMLF</a>) reports sales in the U.S. rose <a href=\"https://seekingalpha.com/pr/17532195-hyundai-motor-america-reports-positive-may-2019-sales\" sasource=\"qp_sum_news_3\" target=\"_blank\">2%</a> in May to 66,121 units.</li><li>Retail sales grew 4% for the month, backed by Tucson +46%, Santa Fe +37%, Kona and Kona EV +41% and Veloster +40%, while fleet sales declined by 5%.</li><li>YTD Hyundai U.S. sales up 1.7% to 264,530 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468674\" data-linked=\"Hyundai May U.S. sales rose 2%\" data-tweet=\"$HYMLF $HYMOF $HYMTF - Hyundai May U.S. sales rose 2% https://seekingalpha.com/news/3468674-hyundai-may-u-s-sales-rose-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3468674-hyundai-may-u-s-sales-rose-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468673\" data-ts=\"1559582551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468673-eyes-on-clothing-stocks-after-share-price-wipeout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eyes on clothing stocks after share price wipeout</a></h4><ul><li>J. Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J.Jill, Inc.'>JILL</a>) fell 73% in May, but as Mitch Nolen points out the the <a href=\"https://twitter.com/mitchnolen/status/1135236387689467904\" target=\"_blank\">carnage</a> across apparel store stocks was widespread.</li><li>Names in the sector that fell off by more than 25% per Nolen include Christopher &amp; Banks (<a href='https://seekingalpha.com/symbol/CBK' title='Christopher & Banks Corporation'>CBK</a> <font color=\"red\">-0.6%</font>), Destination Maternity (<a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color=\"red\">-3.8%</font>), Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch Co.'>ANF</a> <font color=\"red\">-2.7%</font>), Tilly's (<a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color=\"green\">+2.8%</font>), Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a> <font color=\"green\">+10.5%</font>), Lands' End (<a href='https://seekingalpha.com/symbol/LE' title='Lands&#39; End, Inc.'>LE</a> <font color=\"red\">-3.2%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color=\"green\">+1.3%</font>) and Citi Trends (<a href='https://seekingalpha.com/symbol/CTRN' title='Citi Trends, Inc.'>CTRN</a> <font color=\"green\">+2.8%</font>).</li><li>Seeking Alpha author <a href=\"https://seekingalpha.com/article/4267862-apparel-stocks-world-pain\" target=\"_blank\">BOOX Research</a> also has its eyes on the sector, calling L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color=\"green\">+0.6%</font>), Gap and Hanesbrands (<a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a> <font color=\"green\">+0.8%</font>) interesting value picks at face value with attractive dividend yields. \"L Brands with a P/E multiple of 9.9x, 0.5x price to sales, EV/EBITDA 6.3X, and a dividend yield at 8% (5.3% forward yield given recent cut) should pop up on many radars,\" notes BOOX.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468673\" data-linked=\"Eyes on clothing stocks after share price wipeout\" data-tweet=\"$JILL $CBKC $DEST - Eyes on clothing stocks after share price wipeout https://seekingalpha.com/news/3468673-eyes-on-clothing-stocks-after-share-price-wipeout?source=tweet\" data-url=\"https://seekingalpha.com/news/3468673-eyes-on-clothing-stocks-after-share-price-wipeout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468670\" data-ts=\"1559581504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468670-apple-wwdc-watch-gets-app-store-ios-goes-dark-mode\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple WWDC: Watch gets App Store, iOS goes Dark Mode</a></h4><ul><li><strong>Mac Pro:</strong> The 2019 Mac Pro (prices starting at $5,999) is redesigned with the classic \"cheese grater\" look and contains an Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='red'>-1.4%</font>) Xeon processor with up to 28 cores, up to 300W of power and cooling, and a max 1.5 TB system memory.</li><li>Apple is offering a custom expansion module MPX Module that can include AMD\u2019s (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+0.6%</font>) Radeon Pro Vega 2 or Radeon Pro Vega 2 Duo.</li><li>Read more specs <a href=\"https://www.theverge.com/2019/6/3/18646424/apple-mac-pro-redesign-new-specs-features-photos-wwdc-2019\" target=\"_blank\">here</a>.</li><li><strong>macOS:</strong> As expected, iTunes is no more with Podcasts, Music, and TV splitting up into three separate apps. The update will come with macOS 10.15.</li><li>Starting with the fall release of Catalina, iPhone apps will be able to run on macOS.</li><li><strong>iOS 13:</strong> Dark mode comes to iOS, app packaging changes to be 50% smaller with 60% faster updates, and there's a \"Quick Path\" swipe type keyboard. Reminders gets predictive (similar to the third-party app Fantastical) to help recommend events to save.</li><li>The entire U.S. will get new Maps by the end of the year with \"select\" other countries getting the rollout next year.</li><li><strong>Watch updates:</strong> Apple Watch gets a few new faces, Audio Books, Voice memos, and a calculator app that lets you calculate a tip or split a bill.</li><li>Apps will be able to run on a Watch independently of a companion iPhone app. The App Store is coming to the wearable for direct installs.</li><li>The streaming audio API addition is interesting in the face of Spotify's (<a href='https://seekingalpha.com/symbol/SPOT' title='Spotify Technology S.A.'>SPOT</a> <font color=\"red\">-1.6%</font>) EU antitrust challenge with SPOT upset it couldn't access the API.</li><li>In health, activity trends will show more data than the monthly view. \"Hearing health\" will warn you if your environment is too loud. A new Cycle tracker is coming to Watch and the Health app with fertility tracking and notifications.</li><li>Apple's (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) <a href=\"https://www.apple.com/apple-events/livestream/?&amp;cid=wwa-us-kwgo-features-slid--wwdc-e&amp;mtid=20925e1t39169&amp;aosid=p238&amp;mnid=sboLe6vBP-dc_mtid_20925e1t39169_pcrid_352985306054_&amp;anonymizeip=set\" target=\"_blank\">WWDC 2019</a> kicks off with the keynote streaming here.</li><li>Post will be updated with the latest announcements at the top.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468670\" data-linked=\"Apple WWDC: Watch gets App Store, iOS goes Dark Mode\" data-tweet=\"$AAPL $INTC $AMD - Apple WWDC: Watch gets App Store, iOS goes Dark Mode https://seekingalpha.com/news/3468670-apple-wwdc-watch-gets-app-store-ios-goes-dark-mode?source=tweet\" data-url=\"https://seekingalpha.com/news/3468670-apple-wwdc-watch-gets-app-store-ios-goes-dark-mode\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468669\" data-ts=\"1559581253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468669-research-frontiers-leads-industrial-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Research Frontiers leads industrial losers</a></h4><ul><li><b>Gainers: </b>None</li><li><b>Losers: </b>Research Frontiers (NASDAQ:<a href='https://seekingalpha.com/symbol/REFR' title='Research Frontiers Incorporated'>REFR</a>) <font color=\"red\">-7%</font>. Select Interior Concepts (NASDAQ:<a href='https://seekingalpha.com/symbol/SIC' title='Select Interior Concepts, Inc.'>SIC</a>) <font color=\"red\">-6%</font>. Orion Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a>) <font color=\"red\">-6%</font>. Kornit Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/KRNT' title='Kornit Digital Ltd.'>KRNT</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468669\" data-linked=\"Research Frontiers leads industrial losers\" data-tweet=\"$REFR $SIC $ORN - Research Frontiers leads industrial losers https://seekingalpha.com/news/3468669-research-frontiers-leads-industrial-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3468669-research-frontiers-leads-industrial-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468668\" data-ts=\"1559581095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468668-russia-requires-tinder-to-provide-user-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Russia requires Tinder to provide user data</a></h4><ul><li>Russia <a href=\"https://www.reuters.com/article/us-russia-tinder/russia-orders-tinder-dating-app-to-share-user-data-on-demand-idUSKCN1T425M?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">adds</a> Match Group's (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) app to a list of entities that have to provide law enforcement agencies with on-demand user data and messages.</li><li>Tinder will have to store user metadata, texts, audio and video messages on servers inside Russia for at least six months.</li><li>Match Group shares are <font color=\"red\">down 2.4%</font> to $67.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468668\" data-linked=\"Russia requires Tinder to provide user data\" data-tweet=\"$MTCH - Russia requires Tinder to provide user data https://seekingalpha.com/news/3468668-russia-requires-tinder-to-provide-user-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468668-russia-requires-tinder-to-provide-user-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468667\" data-ts=\"1559580953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468667-spirit-mta-reit-and-yintech-investment-holdings-only-financial-gainers-conifer-holdings-leads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spirit MTA REIT and Yintech Investment Holdings the only financial gainers, Conifer Holdings leads losers</a></h4><ul><li><b>Gainers:</b> Spirit MTA REIT (NYSE:<a href='https://seekingalpha.com/symbol/SMTA' title='Spirit MTA REIT'>SMTA</a>) <font color=\"green\">+17%</font>. Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Conifer Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CNFR' title='Conifer Holdings, Inc.'>CNFR</a>) <font color=\"red\">-18%</font>. Altisource Asset Management (NYSEMKT:<a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corporation'>AAMC</a>) <font color=\"red\">-12%</font>. ATIF Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ATIF' title='ATIF Holdings Limited'>ATIF</a>) <font color=\"red\">-8%</font>. Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology Limited'>AIHS</a>) <font color=\"red\">-7%</font>. Golden Bull (NASDAQ:<a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Limited'>DNJR</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468667\" data-linked=\"Spirit MTA REIT and Yintech Investment Holdings the only financial gainers, Conifer Holdings leads losers\" data-tweet=\"$SMTA $YIN $CNFR - Spirit MTA REIT and Yintech Investment Holdings the only financial gainers, Conifer Holdings leads losers https://seekingalpha.com/news/3468667-spirit-mta-reit-and-yintech-investment-holdings-only-financial-gainers-conifer-holdings-leads?source=tweet\" data-url=\"https://seekingalpha.com/news/3468667-spirit-mta-reit-and-yintech-investment-holdings-only-financial-gainers-conifer-holdings-leads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468666\" data-ts=\"1559580869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENB\" target=\"_blank\">ENB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468666-minnesota-court-rules-enbridge-line-3-environmental-review-inadequate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Minnesota court rules Enbridge Line 3 environmental review inadequate</a></h4><ul><li>Enbridge (<a href='https://seekingalpha.com/symbol/ENB' title='Enbridge Inc.'>ENB</a> <font color='red'>-3.9%</font>) tumbles after the Minnesota Court of Appeals reverses a ruling by the state's Public Utilities Commission on the environmental impact statement for the Line 3 oil pipeline.</li><li>The court says the project's EIS, which was approved last year by the PUC, is \"inadequate because it didn't address the potential impact of an oil spill into the Lake Superior watershed.\"</li><li>ENB's Line 3 project calls for the construction of a new pipeline to carry Canadian oil across Minnesota to Superior, Wis., doubling capacity to 760K bbl/day.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468666\" data-linked=\"Minnesota court rules Enbridge Line 3 environmental review inadequate\" data-tweet=\"$ENB - Minnesota court rules Enbridge Line 3 environmental review inadequate https://seekingalpha.com/news/3468666-minnesota-court-rules-enbridge-line-3-environmental-review-inadequate?source=tweet\" data-url=\"https://seekingalpha.com/news/3468666-minnesota-court-rules-enbridge-line-3-environmental-review-inadequate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>90&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468665\" data-ts=\"1559580297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468665-healthcare-and-tech-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare and Tech dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) <font color=\"green\">+45%</font>. Mirati Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a>) <font color=\"green\">+34%</font>. Cypress Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>) <font color=\"green\">+25%</font>. ARCA biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a>) <font color=\"green\">+23%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"green\">+18%</font>. Spirit MTA REIT (NYSE:<a href='https://seekingalpha.com/symbol/SMTA' title='Spirit MTA REIT'>SMTA</a>) <font color=\"green\">+18%</font>. El Paso Electric (NYSE:<a href='https://seekingalpha.com/symbol/EE' title='El Paso Electric Company'>EE</a>) <font color=\"green\">+14%</font>. ASLAN Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals Limited'>ASLN</a>) <font color=\"green\">+14%</font>. Alexco Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corp.'>AXU</a>) <font color=\"green\">+12%</font>. Eldorado Gold Corporation (NYSE:<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>DelMar Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a>) <font color=\"red\">-50%</font>. Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a>) <font color=\"red\">-31%</font>. Stellar Biotechnologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SBOT' title='Stellar Biotechnologies, Inc.'>SBOT</a>) <font color=\"red\">-24%</font>. Sierra Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SRRA' title='Sierra Oncology, Inc.'>SRRA</a>) <font color=\"red\">-24%</font>. Mesa Laboratories (NASDAQ:<a href='https://seekingalpha.com/symbol/MLAB' title='Mesa Laboratories, Inc.'>MLAB</a>) <font color=\"red\">-23%</font>. Support.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SPRT' title='Support.com, Inc.'>SPRT</a>) <font color=\"red\">-19%</font>. Adynxx (NASDAQ:<a href='https://seekingalpha.com/symbol/ADYX' title='Adynxx, Inc.'>ADYX</a>) <font color=\"red\">-19%</font>. Conifer Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CNFR' title='Conifer Holdings, Inc.'>CNFR</a>) <font color=\"red\">-18%</font>. Eltek (NASDAQ:<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a>) <font color=\"red\">-18%</font>. Cyclerion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CYCN' title='Cyclerion Therapeutics, Inc.'>CYCN</a>) <font color=\"red\">-17%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3468665\" data-linked=\"Healthcare and Tech dominate midday movers\" data-tweet=\"$GNCA $MRTX $CY - Healthcare and Tech dominate midday movers https://seekingalpha.com/news/3468665-healthcare-and-tech-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3468665-healthcare-and-tech-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468664\" data-ts=\"1559580083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBLU\" target=\"_blank\">JBLU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468664-jetblue-considers-a321lr-for-atlantic-hop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JetBlue considers A321LR for Atlantic hop</a></h4><ul><li>JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='red'>-0.1%</font>) is looking at the potential to convert some existing Airbus SE aircraft orders into a longer-range version of the A321LR, according to Bloomberg.</li><li>The company has 85 A321neo aircraft on order, of which a certain percentage could be converted.</li><li>The airline plans to start daily flights between New York and Boston to London airport sometime in 2021.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468664\" data-linked=\"JetBlue considers A321LR for Atlantic hop\" data-tweet=\"$JBLU - JetBlue considers A321LR for Atlantic hop https://seekingalpha.com/news/3468664-jetblue-considers-a321lr-for-atlantic-hop?source=tweet\" data-url=\"https://seekingalpha.com/news/3468664-jetblue-considers-a321lr-for-atlantic-hop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468661\" data-ts=\"1559579821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLK\" target=\"_blank\">XLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468661-semis-gain-on-cypress-sale-amd-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semis gain on Cypress sale, AMD deal</a></h4><ul><li>The Philadelphia Semiconductor Index <font color=\"green\">gains 0.7%</font> compared to the<font color=\"red\"> 0.9% drop</font> for the tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>).</li><li>Semis are gaining after Infineon's \u20ac9B <a href=\"https://seekingalpha.com/news/3468449-infineon-buy-cypress-semi-deal-valued-9b\" target=\"_blank\">acquisition</a> of Cypress Semi and AMD's <a href=\"https://seekingalpha.com/news/3468577-amd-plus-6_7-percent-mobile-tie-samsung\" target=\"_blank\">mobile partnership</a> with Samsung.</li><li>Related semi ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3468661\" data-linked=\"Semis gain on Cypress sale, AMD deal\" data-tweet=\"$XLK $XLK $SOXL - Semis gain on Cypress sale, AMD deal https://seekingalpha.com/news/3468661-semis-gain-on-cypress-sale-amd-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3468661-semis-gain-on-cypress-sale-amd-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468656\" data-ts=\"1559579431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468656-bluebirds-gene-therapy-conditionally-okd-in-europe-for-blood-disorder-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluebird&#39;s gene therapy conditionally OK&#39;d in Europe for blood disorder; shares up 3%</a></h4><ul><li>The European Commission <a href=\"https://seekingalpha.com/pr/17531984-bluebird-bio-announces-eu-conditional-marketing-authorization-zynteglo-autologous-cd34-plus\" target=\"_blank\">conditionally approves</a> bluebird bio's (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color=\"green\">+2.8%</font>) gene therapy ZYNTEGLO (autologous CD34+ cells encoding β<sup>A-T87Q</sup>-globin gene) for the treatment of patients at least 12 years old with transfusion-dependent β-thalassemia who do not have a β<sup>0</sup>/β<sup>0</sup> genotype, for whom hematopoietic stem cell transplantation &#40;HSCT&#41; is appropriate but a human leukocyte antigen &#40;HLA&#41;-matched HSCT donor is not available.</li><li><a href=\"https://ghr.nlm.nih.gov/condition/beta-thalassemia\" target=\"_blank\">Beta thalassemia</a> is an inherited disorder characterized by the insufficient production of hemoglobin. Sufferers are anemic due to the low level of red blood cells.</li><li>The approval is conditional because it was based on less data under PRIME status (akin to Breakthrough Therapy in the U.S.). Two Phase 3 trials and a long-term follow-up study are ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468656\" data-linked=\"Bluebird&#39;s gene therapy conditionally OK&#39;d in Europe for blood disorder; shares up 3%\" data-tweet=\"$BLUE - Bluebird&#39;s gene therapy conditionally OK&#39;d in Europe for blood disorder; shares up 3% https://seekingalpha.com/news/3468656-bluebirds-gene-therapy-conditionally-okd-in-europe-for-blood-disorder-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3468656-bluebirds-gene-therapy-conditionally-okd-in-europe-for-blood-disorder-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468652\" data-ts=\"1559578964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APA\" target=\"_blank\">APA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468652-cheniere-apache-sign-natural-gas-supply-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheniere, Apache sign natural gas supply deal</a></h4><ul><li>Apache (<a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a> <font color='green'>+1.9%</font>) says it will sell 140K MMBtu/day of natural gas to Cheniere Energy's (<a href='https://seekingalpha.com/symbol/LNG' title='Cheniere Energy, Inc.'>LNG</a> <font color='green'>+2.7%</font>) Corpus Christi Liquefaction Stage 3 to be used in marketing 850K mt/year of LNG.</li><li>Cheniere will market the liquefied natural gas overseas while APA will receive an LNG price minus a fixed liquefaction fee and other costs.</li><li>Corpus Christi Stage 3 is being developed to include up to seven midscale liquefaction trains with a total expected nominal production capacity of 9.5M mt/year.</li><li>Separately, Cheniere said it made a final investment decision to build a sixth production train at its Sabine Pass LNG export terminal in Louisiana and raised its total company-wide production guidance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468652\" data-linked=\"Cheniere, Apache sign natural gas supply deal\" data-tweet=\"$APA $LNG - Cheniere, Apache sign natural gas supply deal https://seekingalpha.com/news/3468652-cheniere-apache-sign-natural-gas-supply-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3468652-cheniere-apache-sign-natural-gas-supply-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468651\" data-ts=\"1559578953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468651-stocks-turn-negative-after-weak-manufacturing-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks turn negative after weak manufacturing data</a></h4><ul><li>All three major U.S. stock averages sink into the red as disappointing construction and manufacturing economic reports add onto trade-war fears.</li><li>The Nasdaq<font color=\"red\"> slides 1.2%</font>, the S&amp;P 500<font color=\"red\"> falls 0.4%</font>, and the Dow <font color=\"red\">slips 0.2%</font>.</li><li>Five of 11 S&amp;P 500 industry sectors now reside in negative territory, with communications services (<font color=\"red\">-2.7%</font>) and consumer discretionary (<font color=\"red\">-1.0%</font>) lagging the most.</li><li>Materials (<font color=\"green\">+1.8%</font>) and energy (<font color=\"green\">+1.0%</font>) outperform the broader markets.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468651\" data-linked=\"Stocks turn negative after weak manufacturing data\" data-tweet=\"Stocks turn negative after weak manufacturing data https://seekingalpha.com/news/3468651-stocks-turn-negative-after-weak-manufacturing-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468651-stocks-turn-negative-after-weak-manufacturing-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468644\" data-ts=\"1559578194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPL\" target=\"_blank\">LPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468644-lg-facing-oled-iphone-delays-reports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LG facing OLED iPhone delays - reports</a></h4><ul><li>LG Display (<a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a> <font color='red'>-0.1%</font>) has reportedly halted its E6-1 manufacturing line in Paju due to technical issues.</li><li>E6-1 was expected to help roll out OLED displays for Apple iPhones later this year, joining Samsung in the supply chain.</li><li>The tech issue might not cause major problems. LG could also get its E6-2 facility online faster to compensate, but that facility uses rival Kateeva's tech while LG's was testing at E6-1.</li><li>Source: <a href=\"https://9to5mac.com/2019/06/03/lg-oled/\" target=\"_blank\">9to5Mac</a> and Korean media reports.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468644\" data-linked=\"LG facing OLED iPhone delays - reports\" data-tweet=\"$LPL - LG facing OLED iPhone delays - reports https://seekingalpha.com/news/3468644-lg-facing-oled-iphone-delays-reports?source=tweet\" data-url=\"https://seekingalpha.com/news/3468644-lg-facing-oled-iphone-delays-reports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468643\" data-ts=\"1559578066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMTOF\" target=\"_blank\">MMTOF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468643-mitsubishi-motors-salesminus-21_5-in-may\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitsubishi Motors sales -21.5% in May</a></h4><ul> <li>Mitsubishi Motors (<a href='https://seekingalpha.com/symbol/MMTOF' title='Mitsubishi Motors Corporation'>OTCPK:MMTOF</a>) <a href=\"https://seekingalpha.com/pr/17531875-mitsubishi-motors-reports-may-2019-sales\" sasource=\"qp_sum_news_4\" target=\"_blank\">reports</a> sales declined 21.5% to 9,750 units in May.</li><li>YTD sales grew 4.6% to 58,780 units.</li><li>Mirage sales decreased 30.7% to 2150 units.</li><li>Outlander sales down 14.1% to 3,840 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468643\" data-linked=\"Mitsubishi Motors sales -21.5% in May\" data-tweet=\"$MMTOF - Mitsubishi Motors sales -21.5% in May https://seekingalpha.com/news/3468643-mitsubishi-motors-salesminus-21_5-in-may?source=tweet\" data-url=\"https://seekingalpha.com/news/3468643-mitsubishi-motors-salesminus-21_5-in-may\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468640\" data-ts=\"1559577853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468640-nektar-up-12-on-positive-bempegaldesleukin-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar up 12% on positive bempegaldesleukin data</a></h4><ul><li>Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color=\"green\">+12.3%</font>) is up on average volume in response to <a href=\"https://seekingalpha.com/pr/17530988-nektar-therapeutics-presents-biomarker-clinical-data-pivotminus-02-phase-2-study\" target=\"_blank\">encouraging data</a> on bempegaldesleukin (NKTR-214) presented at ASCO.</li><li>Month 12 follow-up results from a Phase 1/2 clinical trial, PIVOT-02, evaluating the CD122-biased IL-2 pathway agonist in combination with Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"green\">+1.8%</font>) Opdivo (nivolumab) in patients with Stage IV (distant metastatic) melanoma in a first-line setting showed a 53% (n=20/38) response rate in evaluable patients, including 13 (34%) complete responders. The disease control rate (responders + stable cancer) was 74% (n=28/38). Median duration of response was not reached at the time of data cut-off.</li><li>On the safety front, The most common treatment-related adverse events were fatigue (65.9%), pyrexia (fever) (61.0%), rash (56.1%), pruritus (itchy skin) (48.8%), nausea (41.5%), influenza-like illness (39.0%), arthralgia (joint pain) (36.6%), chills (34.1%) and myalgia (muscle pain) (31.7%). 14.6% (n=6/41) of treated patients experienced a serious or life-threatening adverse event. The discontinuation rate was 9.8% (n=4/41).</li><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03635983?term=NCT03635983&amp;rank=1\" target=\"_blank\">Phase 3 study</a> assessing bempegaldesleukin + nivolumab compared to nivolumab alone in first-line melanoma is currently recruiting patients as is a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03785925?term=NCT03785925&amp;rank=1\" target=\"_blank\">Phase 2</a> in first-line metastatic urothelial cancer.</li><li>#ASCO19</li></ul><div class=\"tiny-share-widget\" data-id=\"3468640\" data-linked=\"Nektar up 12% on positive bempegaldesleukin data\" data-tweet=\"$NKTR $BMY - Nektar up 12% on positive bempegaldesleukin data https://seekingalpha.com/news/3468640-nektar-up-12-on-positive-bempegaldesleukin-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468640-nektar-up-12-on-positive-bempegaldesleukin-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468639\" data-ts=\"1559577810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468639-pitney-bowes-and-tenneco-among-consumer-gainers-nio-and-natural-health-trends-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pitney Bowes and Tenneco among consumer gainers; NIO and Natural Health Trends among losers</a></h4><ul><li><b>Gainers: </b>Lifeway Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/LWAY' title='Lifeway Foods, Inc.'>LWAY</a>) <font color=\"green\">+12%</font>. Pitney Bowes (NYSE:<a href='https://seekingalpha.com/symbol/PBI' title='Pitney Bowes Inc.'>PBI</a>) <font color=\"green\">+9%</font>. Hyster-Yale Materials Handling (NYSE:<a href='https://seekingalpha.com/symbol/HY' title='Hyster-Yale Materials Handling, Inc.'>HY</a>) <font color=\"green\">+7%</font>. Cooper-Standard Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CPS' title='Cooper-Standard Holdings Inc.'>CPS</a>) <font color=\"green\">+7%</font>. Tenneco (NYSE:<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>KBS Fashion Group (NASDAQ:<a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a>) <font color=\"red\">-11%</font>. The Alkaline Water Company (NASDAQ:<a href='https://seekingalpha.com/symbol/WTER' title='The Alkaline Water Company Inc.'>WTER</a>) <font color=\"red\">-8%</font>. Natural Health Trends (NASDAQ:<a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a>) <font color=\"red\">-8%</font>. Universal Electronics (NASDAQ:<a href='https://seekingalpha.com/symbol/UEIC' title='Universal Electronics Inc.'>UEIC</a>) <font color=\"red\">-7%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468639\" data-linked=\"Pitney Bowes and Tenneco among consumer gainers; NIO and Natural Health Trends among losers\" data-tweet=\"$LWAY $PBI $HY - Pitney Bowes and Tenneco among consumer gainers; NIO and Natural Health Trends among losers https://seekingalpha.com/news/3468639-pitney-bowes-and-tenneco-among-consumer-gainers-nio-and-natural-health-trends-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3468639-pitney-bowes-and-tenneco-among-consumer-gainers-nio-and-natural-health-trends-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468635\" data-ts=\"1559577422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468635-ftc-to-lead-facebook-probes-doj-lead-on-google\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTC to lead Facebook probes; DOJ has lead on Google</a></h4><ul>   <li>The Federal Trade Commission has <a href=\"https://www.wsj.com/articles/ftc-to-examine-how-facebook-s-practices-affect-digital-competition-11559576731?mod=hp_lead_pos1\" target=\"_blank\">secured the right</a> to scrutinize Facebook's (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color=\"red\">-4.3%</font>) effects on digital competition, <i>The Wall Street Journal</i> reports.</li>    <li>The news is a companion of sorts to the report that a <a href=\"https://seekingalpha.com/news/3468424-doj-preparing-google-antitrust-probe-deal-ftc-bloomberg\" target=\"_blank\">deal between the FTC and Justice Dept.</a> means DOJ will have the lead on examining antitrust issues at Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color=\"red\">-5.7%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color=\"red\">-5.7%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3468635\" data-linked=\"FTC to lead Facebook probes; DOJ has lead on Google\" data-tweet=\"$GOOG $GOOGL $FB - FTC to lead Facebook probes; DOJ has lead on Google https://seekingalpha.com/news/3468635-ftc-to-lead-facebook-probes-doj-lead-on-google?source=tweet\" data-url=\"https://seekingalpha.com/news/3468635-ftc-to-lead-facebook-probes-doj-lead-on-google\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>89&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468631\" data-ts=\"1559577127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468631-stocks-still-mixed-though-gap-narrows\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks still mixed, though gap narrows</a></h4><ul><li>S&amp;P 500 and Dow's gains and Nasdaq's loss moderate a bit heading into noon trading as materials stocks outperform the broader market and communications services lag.</li><li>The S&amp;P 500 is flat, the Dow edges <font color=\"green\">up 0.1% </font>and the Nasdaq <font color=\"red\">falls 0.6%</font>.</li><li>By industry sector, materials (<font color=\"green\">+1.8%</font>), energy (<font color=\"green\">+1.0%</font>), and health care (<font color=\"green\">+1.0%</font>) outpace the market, while communications services (<font color=\"red\">-1.9%</font>) and consumer discretionary (<font color=\"red\">-0.4%</font>)  light up red.</li><li>Crude oil <font color=\"red\">falls 0.3%</font> to $53.34 per barrel.</li><li>10-year Treasury yield falls 2 basis points to 2.126%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468631\" data-linked=\"Stocks still mixed, though gap narrows\" data-tweet=\"Stocks still mixed, though gap narrows https://seekingalpha.com/news/3468631-stocks-still-mixed-though-gap-narrows?source=tweet\" data-url=\"https://seekingalpha.com/news/3468631-stocks-still-mixed-though-gap-narrows\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468630\" data-ts=\"1559577046\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSAT\" target=\"_blank\">VSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468630-viasat-visiontec-partner-on-brazilian-satellite-internet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viasat, Visiontec partner on Brazilian satellite Internet</a></h4><ul>   <li>Viasat (<a href=\"http://seekingalpha.com/symbol/VSAT\" target=\"_blank\">VSAT</a> <font color=\"green\">+1.8%</font>) is partnering with Brazilian distributor Visiontec on an offering of <a href=\"https://seekingalpha.com/pr/17531506-viasat-visiontec-partner-bring-high-speed-high-quality-satellite-internet-brazil\" target=\"_blank\">high-speed satellite Internet service</a>.</li>    <li>Visiontec is currently installing Viasat broadband gear in remote schools, hospitals and government facilities, and Viasat will provide the ground network and infrastructure to power a Telebras-owned satellite.</li>    <li>Visiontec has provided services in country for 27 years and has an extensive distribution network.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3468630\" data-linked=\"Viasat, Visiontec partner on Brazilian satellite Internet\" data-tweet=\"$VSAT - Viasat, Visiontec partner on Brazilian satellite Internet https://seekingalpha.com/news/3468630-viasat-visiontec-partner-on-brazilian-satellite-internet?source=tweet\" data-url=\"https://seekingalpha.com/news/3468630-viasat-visiontec-partner-on-brazilian-satellite-internet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468622\" data-ts=\"1559576135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/E\" target=\"_blank\">E</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468622-eni-strikes-oil-again-offshore-angola\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eni strikes oil again offshore Angola</a></h4><ul><li>Eni (<a href='https://seekingalpha.com/symbol/E' title='Eni S.p.A.'>E</a> <font color='green'>+3.1%</font>) announces its fifth oil discovery in the past year from Angola's deepwater Block 15.</li><li>Eni says the discovery occurred at the Agidigbo prospect near its existing West Hub development, with post-drill results indicating 300M-400M barrels of light oil in place.</li><li>The area's five discoveries combined contain as much as 1.8B barrels of light oil in place with possible upside.</li><li>Eni is operator of Block 15 and owns a 36.8% stake, with an equal portion held by Angola's Sonangol P&amp;P.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468622\" data-linked=\"Eni strikes oil again offshore Angola\" data-tweet=\"$E - Eni strikes oil again offshore Angola https://seekingalpha.com/news/3468622-eni-strikes-oil-again-offshore-angola?source=tweet\" data-url=\"https://seekingalpha.com/news/3468622-eni-strikes-oil-again-offshore-angola\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468617\" data-ts=\"1559575181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468617-national-beverageplus-2-after-maxim-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage +2% after Maxim upgrade</a></h4><ul><li>Maxim Group hikes National Beverage Corp. (<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='green'>+1.9%</font>) to a Hold rating after having the beverage stock set at Sell.</li><li>While Maxim is still cautious on the potential for \"stagnant\" growth at FIZZ, the 36% YTD share price drop moves the firm off its bear call.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468617\" data-linked=\"National Beverage +2% after Maxim upgrade\" data-tweet=\"$FIZZ - National Beverage +2% after Maxim upgrade https://seekingalpha.com/news/3468617-national-beverageplus-2-after-maxim-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3468617-national-beverageplus-2-after-maxim-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468614\" data-ts=\"1559574796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CODI\" target=\"_blank\">CODI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468614-compass-diversifiedplus-8_7-barrons-highlights-dividend-yield\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Compass Diversified +8.7% as Barron&#39;s highlights dividend yield</a></h4><ul><li>Compass Diversified (NYSE:<a href='https://seekingalpha.com/symbol/CODI' title='Compass Diversified Holdings LLC'>CODI</a>) <font color=\"green\">jumps 8.7%</font> after a Barron's article over the weekend flags the stock's \"huge\" dividend yield and suggests it would be \"a good way to avoid the trade war.\"</li><li>Jeff John, senior portfolio manager of the American Century Small Cap Value fund, which owns about 4% of Compass, says CODI is \"overlooked\" by the market; he figures it's worth $21.</li><li><a href=\"https://seekingalpha.com/symbol/CODI/dividends/scorecard\" target=\"_blank\">Forward dividend yield </a>of 9.26% vs. <a href=\"https://seekingalpha.com/symbol/CODI/valuation\" target=\"_blank\">sector median of 2.77%</a>.</li><li><a href=\"https://seekingalpha.com/symbol/CODI/ratings/quant-ratings\" target=\"_blank\">Qaunt rating</a>: Very Bullish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468614\" data-linked=\"Compass Diversified +8.7% as Barron&#39;s highlights dividend yield\" data-tweet=\"$CODI - Compass Diversified +8.7% as Barron&#39;s highlights dividend yield https://seekingalpha.com/news/3468614-compass-diversifiedplus-8_7-barrons-highlights-dividend-yield?source=tweet\" data-url=\"https://seekingalpha.com/news/3468614-compass-diversifiedplus-8_7-barrons-highlights-dividend-yield\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468613\" data-ts=\"1559574713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSANY\" target=\"_blank\">NSANY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468613-nissan-group-u-s-salesplus-0_1-in-may\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nissan Group U.S. sales +0.1% in May</a></h4><ul><li>Nissan (<a href='https://seekingalpha.com/symbol/NSANY' title='Nissan Motor Co., Ltd.'>OTCPK:NSANY</a>) unit sales <a href=\"https://seekingalpha.com/pr/17532131-nissan-group-reports-may-2019-u-s-sales\" sasource=\"qp_sum_news_13\" target=\"_blank\">+0.1%</a> to 131,983 units vs. -6.8% forecast by Edmunds.</li><li>Nissan truck sales grew 0.1% Y/Y to 66,820 units.</li><li>Nissan car sales up 2.4% to 54,750 units.</li><li>Sales growth by brand: Nissan +1.1% to 121,570 units; Infiniti -10.4% to 10,413 units.</li><li>Nissan Altima sales rose 5.2% and Maxima declined 41.7% for the month.</li><li>Rogue sales decreased 25.5% to 28,600 units during the month.</li><li>Titan sales squeezed 15.6% to 3,189 units.</li><li>YTD Nissan sales fell 5.9% to 540,313 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468613\" data-linked=\"Nissan Group U.S. sales +0.1% in May\" data-tweet=\"$NSANY $NSANF - Nissan Group U.S. sales +0.1% in May https://seekingalpha.com/news/3468613-nissan-group-u-s-salesplus-0_1-in-may?source=tweet\" data-url=\"https://seekingalpha.com/news/3468613-nissan-group-u-s-salesplus-0_1-in-may\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468609\" data-ts=\"1559574252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468609-novartis-up-2-on-updated-capmatinib-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis up 2% on updated capmatinib data</a></h4><ul><li>Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"green\">+2%</font>) perks up on below-average volume on the heels of <a href=\"https://seekingalpha.com/pr/17531104-novartis-shows-growing-strength-lung-cancer-innovation-new-capmatinib-investigational-data\" target=\"_blank\">positive data</a> presented at ASCO on lung cancer candidate capmatinib.</li><li>Results from a Phase 2 study, GEOMETRY mono-1, evaluating the MET inhibitor in patients with locally advanced/metastatic non-small cell lung cancer &#40;NSCLC&#41; that harbor a MET exon-14-skipping mutation showed a treatment effect. In a cohort of treatment-naive patients, the overall response rate &#40;ORR&#41; was 68% (n=19/28). The ORR in a cohort of previously treated subjects was 41% (n=28/69). Median duration of responses were 11.1 months and 9.7 months, respectively.</li><li>On the safety front, the most frequent adverse events (occurred in 84% of treated patients), were peripheral edema (42%), nausea (33%), creatinine (biomarker for kidney function) increase (20%), vomiting (19%), fatigue (14%), decreased appetite (13%) and diarrhea (11%). 36% of patients experienced a serious or life-threatening (4.5%) adverse event.</li><li>MET-positive NSCLC, an aggressive form of the cancer, represents ~3-4% of total NSCLC cases.</li><li>Discussions with global regulatory authorities are in process.</li><li>#ASCO19</li></ul><div class=\"tiny-share-widget\" data-id=\"3468609\" data-linked=\"Novartis up 2% on updated capmatinib data\" data-tweet=\"$NVS - Novartis up 2% on updated capmatinib data https://seekingalpha.com/news/3468609-novartis-up-2-on-updated-capmatinib-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468609-novartis-up-2-on-updated-capmatinib-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468610\" data-ts=\"1559574222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TM\" target=\"_blank\">TM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468610-toyota-motor-u-s-sales-rises-3_2-in-may\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toyota Motor U.S. sales rises 3.2% in May</a></h4><ul><li>Toyota (<a href='https://seekingalpha.com/symbol/TM' title='Toyota Motor Corporation'>TM</a> <font color='green'>+0.2%</font>) unit sales <a href=\"https://seekingalpha.com/pr/17531986-toyota-motor-north-america-reports-may-2019-sales\" sasource=\"qp_sum_news_12\" target=\"_blank\">+3.2%</a> to 222,174 units vs. -0.3% forecast by Edmunds.</li><li>YTD unit sales down 3.1% to 949,756 units.</li><li>Toyota division sales rose 4.1% to 197,637 units.</li><li>Lexus division sales fell 3.4% to 24,537 units.</li><li>Total YARIS sales dropped 1.6% to 2,953 units.</li><li>Total Corolla sales slipped 13.1% to 25,712 units.</li><li>Camry sales expanded 20.8% to 36,208 units.</li><li>Prius sales contracted 23.7% to 6,615 units.</li><li>On the SUV front, RAV4 sales +3.9%, Highlander sales +1.1% and Land Cruiser +10.4%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468610\" data-linked=\"Toyota Motor U.S. sales rises 3.2% in May\" data-tweet=\"$TM - Toyota Motor U.S. sales rises 3.2% in May https://seekingalpha.com/news/3468610-toyota-motor-u-s-sales-rises-3_2-in-may?source=tweet\" data-url=\"https://seekingalpha.com/news/3468610-toyota-motor-u-s-sales-rises-3_2-in-may\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468608\" data-ts=\"1559574179\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468608-mimedx-group-and-arca-biopharma-among-healthcare-gainers-stellar-biotechnologies-and-aduro\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx Group and ARCA biopharma among healthcare gainers; Stellar Biotechnologies and Aduro BioTech among losers</a></h4><ul><li><b>Gainers: </b>Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) <font color=\"green\">+54%</font>. Mirati Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a>) <font color=\"green\">+36%</font>. ARCA biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a>) <font color=\"green\">+29%.</font> MiMedx Group (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group, Inc.'>OTC:MDXG</a>) <font color=\"green\">+13%</font>. Provention Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/PRVB' title='Provention Bio, Inc.'>PRVB</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>DelMar Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a>) <font color=\"red\">-43%</font>. Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a>) <font color=\"red\">-28%</font>. Stellar Biotechnologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SBOT' title='Stellar Biotechnologies, Inc.'>SBOT</a>) <font color=\"red\">-21%</font>. Five Prime Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a>) <font color=\"red\">-18%</font>. Adynxx (NASDAQ:<a href='https://seekingalpha.com/symbol/ADYX' title='Adynxx, Inc.'>ADYX</a>) <font color=\"red\">-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468608\" data-linked=\"MiMedx Group and ARCA biopharma among healthcare gainers; Stellar Biotechnologies and Aduro BioTech among losers\" data-tweet=\"$GNCA $MRTX $ABIO - MiMedx Group and ARCA biopharma among healthcare gainers; Stellar Biotechnologies and Aduro BioTech among losers https://seekingalpha.com/news/3468608-mimedx-group-and-arca-biopharma-among-healthcare-gainers-stellar-biotechnologies-and-aduro?source=tweet\" data-url=\"https://seekingalpha.com/news/3468608-mimedx-group-and-arca-biopharma-among-healthcare-gainers-stellar-biotechnologies-and-aduro\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468602\" data-ts=\"1559573663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MZDAY\" target=\"_blank\">MZDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468602-mazda-u-s-sales-dropped-16-in-may\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mazda U.S. sales dropped 16% in May</a></h4><ul><li>Mazda (<a href='https://seekingalpha.com/symbol/MZDAY' title='Mazda Motor Corporation'>OTCPK:MZDAY</a>) unit sales <a href=\"https://seekingalpha.com/pr/17532073-mazda-reports-may-sales-results\" sasource=\"qp_sum_news_4\" target=\"_blank\">-16%</a> Y/Y in May to 25,192 units.</li><li>Car sales decreased 30.8% to 7,943 units.</li><li>Truck sales down 6.8% to 17,249 units.</li><li>YTD Mazda U.S. sales slipped 15.5% to 115,727 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468602\" data-linked=\"Mazda U.S. sales dropped 16% in May\" data-tweet=\"$MZDAY $MZDAF - Mazda U.S. sales dropped 16% in May https://seekingalpha.com/news/3468602-mazda-u-s-sales-dropped-16-in-may?source=tweet\" data-url=\"https://seekingalpha.com/news/3468602-mazda-u-s-sales-dropped-16-in-may\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468601\" data-ts=\"1559573561\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMCX\" target=\"_blank\">AMCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468601-amc-networksplus-2_5-imperial-sees-lack-of-growth-priced-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC Networks +2.5% as Imperial sees lack of growth priced in</a></h4><ul>   <li>Imperial Capital has upgraded AMC Networks (<a href=\"http://seekingalpha.com/symbol/AMCX\" target=\"_blank\">AMCX</a> <font color=\"green\">+2.5%</font>) to In-line based on valuation after its 2019 declines.</li>    <li>A drop of 15% since the firm downgraded in January means that a lack of operating income growth is priced in, analyst David Miller says. He also adds that the network's upfront announcement of a third <i>Walking Dead</i> series \"essentially got lost in the shuffle\" and wanted to make sure investors were aware of that, and 2020 plans for <i>Walking Dead</i> theatrical films. (h/t Bloomberg)</li>    <li>He's keeping a $53 price target, vs. a current price of $54.08.</li>    <li><a href=\"https://seekingalpha.com/symbol/AMCX/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha authors</a> tend to be bullish on the stock, vs. a <a href=\"https://seekingalpha.com/symbol/AMCX/ratings/quant-ratings\" target=\"_blank\">Quant rating of Neutral</a> and <a href=\"https://seekingalpha.com/symbol/AMCX/ratings/sell-side-ratings\" target=\"_blank\">sell-side consensus of Hold</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3468601\" data-linked=\"AMC Networks +2.5% as Imperial sees lack of growth priced in\" data-tweet=\"$AMCX - AMC Networks +2.5% as Imperial sees lack of growth priced in https://seekingalpha.com/news/3468601-amc-networksplus-2_5-imperial-sees-lack-of-growth-priced-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3468601-amc-networksplus-2_5-imperial-sees-lack-of-growth-priced-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468598\" data-ts=\"1559572877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRUE\" target=\"_blank\">TRUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468598-truecar-bid-down-after-ceo-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TrueCar bid down after CEO exit</a></h4><ul><li>TrueCar (NASDAQ:<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc.'>TRUE</a>) is <font color=\"red\">down 9.33%</font> and traded as low as $5.87 earlier in the session following the retirement announcement of CEO Chip Perry.</li><li>TrueCar says Perry plans to continue supporting the company in an advisory capacity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468598\" data-linked=\"TrueCar bid down after CEO exit\" data-tweet=\"$TRUE - TrueCar bid down after CEO exit https://seekingalpha.com/news/3468598-truecar-bid-down-after-ceo-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3468598-truecar-bid-down-after-ceo-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468597\" data-ts=\"1559572822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMC\" target=\"_blank\">HMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468597-american-honda-sales-declined-4_9-in-may\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Honda sales declined 4.9% in May</a></h4><ul><li>Honda (<a href='https://seekingalpha.com/symbol/HMC' title='Honda Motor Co., Ltd.'>HMC</a> <font color='green'>+1%</font>) unit sales <a href=\"https://seekingalpha.com/pr/17532034-american-honda-announces-may-sales-results\" sasource=\"qp_sum_news_10\" target=\"_blank\">-4.9%</a> to 145,532 units vs. -3.1% forecast by Edmunds.</li><li>Sales squeezed 7.4% for cars and 2.7% for trucks.</li><li>Sales in the Honda division fell 5.9% to 131,985 units, while Acura sales rose 5.7% to 13,547 units.</li><li>Civic sales down 4.5% and Accord -15.3% for the month.</li><li>YTD Honda sales flat at 641,094 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468597\" data-linked=\"American Honda sales declined 4.9% in May\" data-tweet=\"$HMC $HNDAF - American Honda sales declined 4.9% in May https://seekingalpha.com/news/3468597-american-honda-sales-declined-4_9-in-may?source=tweet\" data-url=\"https://seekingalpha.com/news/3468597-american-honda-sales-declined-4_9-in-may\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468594\" data-ts=\"1559572662\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMS\" target=\"_blank\">SGMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468594-scientific-gamesplus-5-on-renewed-branding-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scientific Games +5% on renewed branding deal</a></h4><ul><li>Scientific Games (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMS' title='Scientific Games Corporation'>SGMS</a>) and Fremantle <a href=\"https://seekingalpha.com/pr/17531927-scientific-games-renews-contract-exclusive-use-iconic-fremantle-tv-game-show-brands-lottery\" target=\"_blank\">renew their agreement</a> allowing SGMS to continue using game show brands The Price is Right, Family Feud, and Press Your Luck in lottery games.</li><li>The new agreement lasts until 2022.</li><li>SGMS shares are <font color=\"green\">up 5%</font> to $20.08.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468594\" data-linked=\"Scientific Games +5% on renewed branding deal\" data-tweet=\"$SGMS - Scientific Games +5% on renewed branding deal https://seekingalpha.com/news/3468594-scientific-gamesplus-5-on-renewed-branding-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3468594-scientific-gamesplus-5-on-renewed-branding-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468547\" data-ts=\"1559570823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNC\" target=\"_blank\">CNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468547-centene-down-8-premarket-on-no-bid-from-humana\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centene down 8% premarket on no-bid from Humana</a></h4><ul><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) slips <font color=\"red\">8%</font> premarket on robust volume on the news that Humana (NYSE:<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a>) will <a href=\"https://finance.yahoo.com/news/humana-says-not-bid-centene-104959885.html\" target=\"_blank\">not make an offer</a> the managed care provider. A month ago, there was <a href=\"https://seekingalpha.com/news/3459530-big-day-centene-takeover-chatter\" target=\"_blank\">chatter</a> that Humana was interested in a friendly takeover if CNC backed away from its planned acquisition of WellCare Health Plans.</li><li><strong>Update</strong>: WellCare (<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color=\"green\">+1.8%</font>) is up on modestly higher volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468547\" data-linked=\"Centene down 8% premarket on no-bid from Humana\" data-tweet=\"$CNC $HUM $WCG - Centene down 8% premarket on no-bid from Humana https://seekingalpha.com/news/3468547-centene-down-8-premarket-on-no-bid-from-humana?source=tweet\" data-url=\"https://seekingalpha.com/news/3468547-centene-down-8-premarket-on-no-bid-from-humana\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468579\" data-ts=\"1559570565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468579-mirati-up-32-on-amgens-kras-inhibitor-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirati up 32% on Amgen&#39;s KRAS inhibitor data</a></h4><ul><li>Mirati Therapeutics (<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color=\"green\">+32.4%</font>) is up on over 40% higher volume in apparent response to <a href=\"https://seekingalpha.com/news/3468564-amgen-4-percent-amg-510-data\" target=\"_blank\">Phase 1 data</a> on Amgen's KRAS<sup>G12C</sup> inhibitor AMG 510 presented at ASCO in Chicago.</li><li>Preliminary results showed only partial responses in five of 10 evaluable patients.</li><li>Investors appear to perceive the somewhat underwhelming data as a positive for Mirati's KRAS<sup>G12C</sup> inhibitor <a href=\"https://seekingalpha.com/news/3463495-mirati-fortunes-kras-inhibitor-tied-amgens-jpmorgan\" target=\"_blank\">MRTX849</a>, currently in IND-enabling studies.</li><li>#ASCO19</li></ul><div class=\"tiny-share-widget\" data-id=\"3468579\" data-linked=\"Mirati up 32% on Amgen&#39;s KRAS inhibitor data\" data-tweet=\"$MRTX - Mirati up 32% on Amgen&#39;s KRAS inhibitor data https://seekingalpha.com/news/3468579-mirati-up-32-on-amgens-kras-inhibitor-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468579-mirati-up-32-on-amgens-kras-inhibitor-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468577\" data-ts=\"1559570400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468577-amdplus-6_7-on-mobile-tie-up-samsung\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD +6.7% on mobile tie-up with Samsung</a></h4><ul><li>AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) and Samsung (<a href='https://seekingalpha.com/symbol/SSNNF' title='Samsung Electronics Co., Ltd.'>OTC:SSNNF</a>,<a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>) <a href=\"https://seekingalpha.com/pr/17531959-amd-samsung-announce-strategic-partnership-ultra-low-power-high-performance-graphics\" target=\"_blank\">announce</a> a multiyear partnership based on AMD's Radeon graphics chips.</li><li>AMD will license its custom graphics IP for Samsung to use in mobile devices. In return, Samsung will pay license fees and royalties.</li><li>AMD shares <font color=\"green\">gain 6.7%</font> to $29.24.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468577\" data-linked=\"AMD +6.7% on mobile tie-up with Samsung\" data-tweet=\"$AMD $SSNNF $SSNLF - AMD +6.7% on mobile tie-up with Samsung https://seekingalpha.com/news/3468577-amdplus-6_7-on-mobile-tie-up-samsung?source=tweet\" data-url=\"https://seekingalpha.com/news/3468577-amdplus-6_7-on-mobile-tie-up-samsung\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>185&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468575\" data-ts=\"1559570396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTD\" target=\"_blank\">FTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468575-ftd-companies-moves-chapter-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTD Companies moves into Chapter 11</a></h4><ul><li>FTD Companies (<a href='https://seekingalpha.com/symbol/FTD' title='FTD Companies, Inc.'>FTD</a> <font color='red'>-70.6%</font>) discloses that it filed for bankruptcy protection in Delaware.</li><li>The company says it intends to use the court-supervised restructuring process to support and protect its ongoing business operations.</li><li>FTD is still running its floral and gift operations through the Chapter 11 process.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468575\" data-linked=\"FTD Companies moves into Chapter 11\" data-tweet=\"$FTD - FTD Companies moves into Chapter 11 https://seekingalpha.com/news/3468575-ftd-companies-moves-chapter-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3468575-ftd-companies-moves-chapter-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468570\" data-ts=\"1559569800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVMK\" target=\"_blank\">SVMK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468570-surveymonkey-hires-autodesk-vet-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SurveyMonkey hires Autodesk vet as CFO</a></h4><ul><li>SurveyMonkey (NASDAQ:<a href='https://seekingalpha.com/symbol/SVMK' title='SVMK Inc.'>SVMK</a>) <a href=\"https://seekingalpha.com/pr/17531930-surveymonkey-hires-autodesk-executive-debbie-clifford-new-chief-financial-officer\" target=\"_blank\">hires </a>Debbie Clifford as Chief Financial Officer, effective July 8.</li><li>Clifford joins SurveyMonkey after 13 years serving in various roles at Autodesk.</li><li>SVMK shares are <font color=\"red\">down 2.4%</font> to $16.94.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468570\" data-linked=\"SurveyMonkey hires Autodesk vet as CFO\" data-tweet=\"$SVMK - SurveyMonkey hires Autodesk vet as CFO https://seekingalpha.com/news/3468570-surveymonkey-hires-autodesk-vet-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3468570-surveymonkey-hires-autodesk-vet-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468564\" data-ts=\"1559569736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468564-amgen-up-4-on-amg-510-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen up 4% on AMG 510 data</a></h4><ul><li>Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"green\">+3.7%</font>) is up in early trade on heels of <a href=\"https://seekingalpha.com/pr/17531858-amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg\" target=\"_blank\">positive, but not overwhelming, data</a> from a Phase 1 clinical trial evaluating KRAS inhibitor AMG 510 in patient with locally-advanced or metastatic KRAS<sup>G12C</sup> -mutant solid tumors. The results were presented at ASCO in Chicago.</li><li>In 10 evaluable patients, five showed partial responses (50% response rate) while four experienced stable cancer implying a 90% (n=9/10) disease control rate.</li><li>The safety profile was favorable.</li><li>The company will host a webcast this evening at 7:30 pm ET to discuss the data presented during the conference.</li><li>#ASCO19</li></ul><div class=\"tiny-share-widget\" data-id=\"3468564\" data-linked=\"Amgen up 4% on AMG 510 data\" data-tweet=\"$AMGN - Amgen up 4% on AMG 510 data https://seekingalpha.com/news/3468564-amgen-up-4-on-amg-510-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468564-amgen-up-4-on-amg-510-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468555\" data-ts=\"1559568487\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATXI\" target=\"_blank\">ATXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468555-avenue-up-16-premarket-on-positive-late-stage-study-of-iv-tramadol\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avenue up 16% premarket on positive late-stage study of IV tramadol</a></h4><ul><li>Thinly traded nano cap Avenue Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATXI' title='Avenue Therapeutics, Inc.'>ATXI</a>) is up <font color=\"green\">16% </font>premarket on light volume in reaction to a <a href=\"https://seekingalpha.com/pr/17531352-avenue-therapeutics-announces-positive-topline-data-second-pivotal-phase-3-study-intravenous\" target=\"_blank\">successful</a> second Phase 3 clinical trial evaluating IV tramadol for the treatment of postoperative pain following abdominoplasty (tummy tuck) surgery.</li><li>The trial met the primary and all key secondary endpoints, demonstrating comparable efficacy to IV morphine.</li><li>The company plans to file its U.S. marketing application in Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468555\" data-linked=\"Avenue up 16% premarket on positive late-stage study of IV tramadol\" data-tweet=\"$ATXI - Avenue up 16% premarket on positive late-stage study of IV tramadol https://seekingalpha.com/news/3468555-avenue-up-16-premarket-on-positive-late-stage-study-of-iv-tramadol?source=tweet\" data-url=\"https://seekingalpha.com/news/3468555-avenue-up-16-premarket-on-positive-late-stage-study-of-iv-tramadol\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468553\" data-ts=\"1559568383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRD\" target=\"_blank\">DRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468553-global-tensions-boost-gold-to-nine-week-highs-gold-miners-gain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global tensions boost gold to nine-week highs; gold miners gain</a></h4><ul><li>Gold prices power to nine-week highs in early morning trade, after last week's global stock market selloff and as U.S. stock futures point to a lower open; Comex gold <font color=\"green\">+0.7%</font> to $1,319.80/oz.</li><li>Gold is finally behaving like a safe haven \"after the trade war escalation led to a code red for global growth,\" says Oanda analyst Edward Moya.</li><li>\"Safe haven buyers are coming back to gold again due to tariff talks,\" says Sharps Pixley CEO Ross Norman. \"Gold has also cruised pretty seamlessly across important levels such as $1,293 and $1,300.\"</li><li>In pre-market trade: <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color=\"green\">+10.3%</font>, <a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Company'>HL</a> <font color=\"green\">+4.6%</font>, <a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a> <font color=\"green\">+3.5%</font>, <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color=\"green\">+2.7%</font>, <a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color=\"green\">+2.7%</font>, <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color=\"green\">+2.4%</font>, <a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color=\"green\">+1.9%</font>, <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color=\"green\">+1.7%</font>, <a href='https://seekingalpha.com/symbol/SAND' title='Sandstorm Gold Ltd.'>SAND</a> <font color=\"green\">+1.6%</font>, <a href='https://seekingalpha.com/symbol/NEM' title='Newmont Goldcorp Corporation'>NEM</a> <font color=\"green\">+1.3%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/AGQ' title='ProShares Ultra Silver ETF'>AGQ</a>, <a href='https://seekingalpha.com/symbol/SIL' title='Global X Silver Miners ETF'>SIL</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/USLV' title='VelocityShares 3x Long Silver ETN'>USLV</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='Aberdn Std Gold Shs'>SGOL</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/ZSL' title='ProShares UltraShort Silver ETF'>ZSL</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/SLVP' title='iShares MSCI Global Silver Miners ETF'>SLVP</a>, <a href='https://seekingalpha.com/symbol/DSLV' title='VelocityShares 3x Inverse Silver ETN'>DSLV</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='Inv DB Mul-Sec Shs Invesco DB Gold Fund'>DGL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3468553\" data-linked=\"Global tensions boost gold to nine-week highs; gold miners gain\" data-tweet=\"$DRD $HL $AUY - Global tensions boost gold to nine-week highs; gold miners gain https://seekingalpha.com/news/3468553-global-tensions-boost-gold-to-nine-week-highs-gold-miners-gain?source=tweet\" data-url=\"https://seekingalpha.com/news/3468553-global-tensions-boost-gold-to-nine-week-highs-gold-miners-gain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468552\" data-ts=\"1559568201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468552-mnkd-cldx-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MNKD, CLDX among premarket gainers</a></h4><ul><li>Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) <font color=\"green\">+94%</font> on positive <a href=\"https://seekingalpha.com/news/3468515-genocea-52-percent-premarket-positive-genminus-009-data-cancer-patients\" target=\"_blank\">GEN-009 data</a> in cancer patients.</li><li>Cypress Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>) <font color=\"green\">+26%</font> as Infineon to <a href=\"https://seekingalpha.com/news/3468449-infineon-buy-cypress-semi-deal-valued-9b\" target=\"_blank\">buy</a> in deal valued at \u20ac9B.</li><li>Outlook Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a>) <font color=\"green\">+24%</font> on manufacturing <a href=\"https://seekingalpha.com/news/3468540-outlook-22-percent-premarket-manufacturing-deal-onsminus-5010\" target=\"_blank\">deal</a> for ONS-5010.</li><li>KBS Fashion (NASDAQ:<a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/news/3468544-kbs-fashion-reports-q1-results\" target=\"_blank\">Q1 results</a>.</li><li>Avenue Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATXI' title='Avenue Therapeutics, Inc.'>ATXI</a>) <font color=\"green\">+18% </font>on positive topline <a href=\"https://seekingalpha.com/pr/17531352-avenue-therapeutics-announces-positive-topline-data-second-pivotal-phase-3-study-intravenous\" target=\"_blank\">data</a> second pivotal Phase 3 trial of IV tramadol in the management of postoperative pain.</li><li>El Paso Electric (NYSE:<a href='https://seekingalpha.com/symbol/EE' title='El Paso Electric Company'>EE</a>) <font color=\"green\">+14%</font> on being <a href=\"https://seekingalpha.com/news/3468512-el-paso-electric-bought-j-p-morgan-infrastructure-fund-68_25-share\" target=\"_blank\">bought</a> by J.P. Morgan infrastructure fund for $68.25/share.</li><li>Medigus (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd.'>MDGS</a>) <font color=\"green\">+12%</font> on MUSE <a href=\"https://seekingalpha.com/news/3468472-medigus-plus-16-percent-premarket-muse-deal-greater-china\" target=\"_blank\">deal</a> in Greater China.</li><li>Sierra Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SRRA' title='Sierra Oncology, Inc.'>SRRA</a>) <font color=\"green\">+9%</font> on positive <a href=\"https://seekingalpha.com/news/3468521-sierra-10-percent-positive-sra737-data\" target=\"_blank\">SRA737 data</a>.</li><li>Palatin Technologies (NYSEMKT:<a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc.'>PTN</a>) <font color=\"green\">+6%</font>.</li><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <font color=\"green\">+6%</font> as Afrezza inhalation powder <a href=\"https://seekingalpha.com/pr/17531563-afrezza-insulin-human-inhalation-powder-approved-brazil\" target=\"_blank\">approved</a> in Brazil.</li><li>Luckin Coffee (NASDAQ:<a href='https://seekingalpha.com/symbol/LK' title='Luckin Coffee Inc.'>LK</a>) <font color=\"green\">+5%</font>.</li><li>Celldex Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc.'>CLDX</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/pr/17531014-celldex-announces-data-cdxminus-3379-clinical-program-presented-asco-2019-promising-biomarker\" target=\"_blank\">presented results</a> from the CDX-3379 clinical program.</li><li>Maxar Technologies  (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc.'>MAXR</a>) <font color=\"green\">+5% </font>on being <a href=\"https://seekingalpha.com/pr/17531185-maxar-earth-intelligence-solutions-expands-support-u-s-national-security-community\" target=\"_blank\">awarded multiple contracts</a> with a total value of more than $95M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468552\" data-linked=\"MNKD, CLDX among premarket gainers\" data-tweet=\"$GNCA $CY $OTLK - MNKD, CLDX among premarket gainers https://seekingalpha.com/news/3468552-mnkd-cldx-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3468552-mnkd-cldx-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468545\" data-ts=\"1559567431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468545-cnc-vicl-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNC, VICL among premarket losers</a></h4><ul><li>DelMar Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a>) <font color=\"red\">-41%</font> on <a href=\"https://seekingalpha.com/news/3468539-delmar-pharmaceuticals-28-percent-equity-offering\" target=\"_blank\">equity offering</a>.</li><li>Vascular Biogenics (NASDAQ:<a href='https://seekingalpha.com/symbol/VBLT' title='Vascular Biogenics Ltd.'>VBLT</a>) <font color=\"red\">-13%</font> as radiographic <a href=\"https://seekingalpha.com/pr/17531526-radiographic-analysis-vbminus-111-phase-2-3-clinical-trials-recurrent-glioblastoma-shows\" target=\"_blank\">analysis</a> of VB-111 Phase 2 and Phase 3 studies in recurrent GBM showed a survival benefit associated with objective responses to the compound and a distinct signature of VB-111 activity.</li><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) <font color=\"red\">-8%</font>.</li><li>Ability (NASDAQ:<a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a>) <font color=\"red\">-8%</font>.</li><li>Eltek (NASDAQ:<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a>) <font color=\"red\">-7%</font>.</li><li>Stellar Biotechnologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SBOT' title='Stellar Biotechnologies, Inc.'>SBOT</a>) <font color=\"red\">-5%</font>.</li><li>Vical (NASDAQ:<a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/pr/17531144-vical-brickell-announce-merger-agreement\" target=\"_blank\">merger</a> with Brickell.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468545\" data-linked=\"CNC, VICL among premarket losers\" data-tweet=\"$DMPI $VBLT $CNC - CNC, VICL among premarket losers https://seekingalpha.com/news/3468545-cnc-vicl-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3468545-cnc-vicl-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468544\" data-ts=\"1559567381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBSF\" target=\"_blank\">KBSF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468544-kbs-fashion-reports-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KBS Fashion reports Q1 results</a></h4><ul><li>KBS Fashion (NASDAQ:<a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a>): Q1 GAAP EPS of $0.135.</li><li>Revenue of $4.62M (+3.6% Y/Y)</li><li>Shares <font color=\"green\">+21.94%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17531881-kbs-fashion-group-limited-reports-robust-first-quarter-2019-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3468544\" data-linked=\"KBS Fashion reports Q1 results\" data-tweet=\"$KBSF - KBS Fashion reports Q1 results https://seekingalpha.com/news/3468544-kbs-fashion-reports-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3468544-kbs-fashion-reports-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468540\" data-ts=\"1559566976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTLK\" target=\"_blank\">OTLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468540-outlook-up-22-premarket-on-manufacturing-deal-for-onsminus-5010\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Outlook up 22% premarket on manufacturing deal for ONS-5010</a></h4><ul><li>Nano cap Outlook Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a>) is up <font color=\"green\">22</font><font color=\"green\">%</font> premarket on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/17531570-outlook-therapeutics-signs-manufacturing-supply-agreement-fujifilm-diosynth-biotechnologies\" target=\"_blank\">agreement </a>with FUJIFILM Diosynth Biotechnologies for the global production of ONS-5010.</li><li>Phase 3-stage ONS-5010, an ophthalmic formulation of Roche's cancer med Avastin (bevacizumab), is being developed to treat wet age-related macular degeneration (wet AMD) and other retinal diseases.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468540\" data-linked=\"Outlook up 22% premarket on manufacturing deal for ONS-5010\" data-tweet=\"$OTLK - Outlook up 22% premarket on manufacturing deal for ONS-5010 https://seekingalpha.com/news/3468540-outlook-up-22-premarket-on-manufacturing-deal-for-onsminus-5010?source=tweet\" data-url=\"https://seekingalpha.com/news/3468540-outlook-up-22-premarket-on-manufacturing-deal-for-onsminus-5010\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468532\" data-ts=\"1559566636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468532-macau-revenue-growth-called-modest-surprise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macau revenue growth called a &#39;modest surprise&#39;</a></h4><ul><li>Nomura Instinet's Harry Curtis weighs in on the <a href=\"https://seekingalpha.com/news/3468434-macau-casinos-return-growth\" target=\"_blank\">+1.8%</a> pace of Macau GGR growth in May.</li><li>\"Positive growth, in light of a softening economic pace in China, is a modest positive surprise. Rhetoric around the trade dispute has worsened so continued growth in Macau, even if modest, should show the underlying strength in mass demand now that junket GGR is solidly negative,\" says Curtis.</li><li>On the positive side, the Macau sector is cruising toward a period of easier monthly GGR comparisons.</li><li>In premarket trading, Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) and Melco Resorts &amp; Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited'>MLCO</a>) are <font color=\"red\">down ~1%</font>. MGM Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>) is <font color=\"red\">down 2.8%</font> and Las Vegas Sands (NYSE:<a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a>) is inactive.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468532\" data-linked=\"Macau revenue growth called a &#39;modest surprise&#39;\" data-tweet=\"$WYNN $MLCO $MGM - Macau revenue growth called a &#39;modest surprise&#39; https://seekingalpha.com/news/3468532-macau-revenue-growth-called-modest-surprise?source=tweet\" data-url=\"https://seekingalpha.com/news/3468532-macau-revenue-growth-called-modest-surprise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468530\" data-ts=\"1559566035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BUD\" target=\"_blank\">BUD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468530-anheuser-busch-inbev-on-watch-after-amid-tariff-jitters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anheuser-Busch InBev on watch after amid tariff jitters</a></h4><ul><li>Anheuser-Busch InBev (NYSE:<a href='https://seekingalpha.com/symbol/BUD' title='Anheuser-Busch InBev SA/NV'>BUD</a>) is <font color=\"red\">down 1.0%</font> in premarket trading as investors continue to gauge the downside from potential tariffs on imports from Mexico.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3468216-beer-stocks-falter-mexico-tariff-teed\" target=\"_blank\">Beer stocks falter after Mexico tariff teed up</a> (May 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3468530\" data-linked=\"Anheuser-Busch InBev on watch after amid tariff jitters\" data-tweet=\"$BUD - Anheuser-Busch InBev on watch after amid tariff jitters https://seekingalpha.com/news/3468530-anheuser-busch-inbev-on-watch-after-amid-tariff-jitters?source=tweet\" data-url=\"https://seekingalpha.com/news/3468530-anheuser-busch-inbev-on-watch-after-amid-tariff-jitters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468529\" data-ts=\"1559565793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468529-sanofis-isatuximab-shows-positive-effect-in-late-stage-mm-study-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi&#39;s isatuximab shows positive effect in late-stage MM study; shares up 1% premarket</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17531052-phase-3-trial-isatuximab-combination-therapy-showed-40-percent-reduction-risk-disease\" target=\"_blank\">Results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02990338?term=icaria-mm&amp;rank=1\" target=\"_blank\">ICARIA-MM</a>, evaluating Sanofi's (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) isatuximab, an anti-CD38 monoclonal antibody, combined with Celgene's Pomalyst (pomalidomide) and dexamethasone in patients with relapsed/refractory multiple myeloma showed a treatment effect. The data were presented at ASCO in Chicago.</li><li>The isatuximab combo increased progression-free survival &#40;PFS&#41; by five months compared to pomalidomide and dexamethasone alone with 40% less risk of cancer progression or death. It also demonstrated a superior objective response rate &#40;ORR&#41;, 60% vs. 35% (p&lt;0.0001).</li><li>The company's European marketing application is currently under EMA review.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li><li>#ASCO19</li></ul><div class=\"tiny-share-widget\" data-id=\"3468529\" data-linked=\"Sanofi&#39;s isatuximab shows positive effect in late-stage MM study; shares up 1% premarket\" data-tweet=\"$SNY - Sanofi&#39;s isatuximab shows positive effect in late-stage MM study; shares up 1% premarket https://seekingalpha.com/news/3468529-sanofis-isatuximab-shows-positive-effect-in-late-stage-mm-study-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3468529-sanofis-isatuximab-shows-positive-effect-in-late-stage-mm-study-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468527\" data-ts=\"1559565787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIG\" target=\"_blank\">BIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468527-big-lotsminus-5-after-baml-turns-bearish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big Lots -5% after BAML turns bearish</a></h4><ul><li>Bank of America Merrill Lynch lowers Big Lots (NYSE:<a href='https://seekingalpha.com/symbol/BIG' title='Big Lots, Inc.'>BIG</a>) to an Underperform rating from Buy in a two-notch lowering.</li><li>\"We believe that the company's outlook for the rest of the year may be too optimistic and could be due for additional cuts,\" warns the BAML analyst team.</li><li>The firm drops its price target to $23 from $45 on its view the stock will continue to struggle until consistent improvement in earnings growth is demonstrated.</li><li>BIG <font color=\"red\">-5.44%</font> premarket to $26.10. The 52-week low is $25.73.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468527\" data-linked=\"Big Lots -5% after BAML turns bearish\" data-tweet=\"$BIG - Big Lots -5% after BAML turns bearish https://seekingalpha.com/news/3468527-big-lotsminus-5-after-baml-turns-bearish?source=tweet\" data-url=\"https://seekingalpha.com/news/3468527-big-lotsminus-5-after-baml-turns-bearish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468521\" data-ts=\"1559565442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRRA\" target=\"_blank\">SRRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468521-sierra-up-10-on-positive-sra737-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sierra up 10% on positive SRA737 data</a></h4><ul> <li>Sierra Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SRRA' title='Sierra Oncology, Inc.'>SRRA</a>) <a href=\"https://seekingalpha.com/pr/17531300-sierra-holds-analyst-and-investor-event-sra737\" target=\"_blank\">holds</a> an analyst and investor event featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit, to discuss clinical findings and possible next steps for its oral, highly selective Chk1 inhibitor, SRA737.</li>    <li>Sierra reported positive preliminary clinical data from its two Phase 1/2 studies of SRA737, as monotherapy and as SRA737+LDG (low dose gemcitabine), at the 2019 Annual Meeting of the American Society of Clinical Oncology &#40;ASCO&#41; in Chicago.</li><li>Anti-cancer activity was demonstrated across multiple indications and genetic contexts, with SRA737+LDG specifically achieving a notable 30% response rate in anogenital cancer patients.</li><li>Additionally, subjects whose tumors harbored FA/BRCA gene network mutations displayed favorable outcomes, including an Overall Response Rate = 25% and Disease Control Rate = 81%.</li> <li>Regulatory clarity for Sierra's lead asset momelotinib is anticipated in the near-term.</li><li>Shares are up <font color=\"green\">10%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468521\" data-linked=\"Sierra up 10% on positive SRA737 data\" data-tweet=\"$SRRA - Sierra up 10% on positive SRA737 data https://seekingalpha.com/news/3468521-sierra-up-10-on-positive-sra737-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3468521-sierra-up-10-on-positive-sra737-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468518\" data-ts=\"1559565116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468518-infineraminus-3_9-jpmorgan-cuts-to-underweight-on-spending-trends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinera -3.9% as JPMorgan cuts to Underweight on spending trends</a></h4><ul>    <li>Infinera (NASDAQ:<a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>) is <font color=\"red\">off 3.9%</font> premarket after a downgrade to Underweight at JPMorgan.</li>    <li>Analyst Samik Chatterjee sees increased risk in cable spending trends in the downgrade.</li>    <li>After a fairly flat start to the year, shares have <font color=\"red\">fallen 22.1%</font> YTD and are <font color=\"red\">down 65.1%</font> over the past year.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3468518\" data-linked=\"Infinera -3.9% as JPMorgan cuts to Underweight on spending trends\" data-tweet=\"$INFN - Infinera -3.9% as JPMorgan cuts to Underweight on spending trends https://seekingalpha.com/news/3468518-infineraminus-3_9-jpmorgan-cuts-to-underweight-on-spending-trends?source=tweet\" data-url=\"https://seekingalpha.com/news/3468518-infineraminus-3_9-jpmorgan-cuts-to-underweight-on-spending-trends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468515\" data-ts=\"1559564826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNCA\" target=\"_blank\">GNCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468515-genocea-up-52-premarket-on-positive-genminus-009-data-in-cancer-patients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genocea up 52% premarket on positive GEN-009 data in cancer patients</a></h4><ul> <li>Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) <a href=\"https://seekingalpha.com/pr/17531345-genocea-s-genminus-009-vaccine-demonstrates-best-class-immune-responses-atlas-selected\" target=\"_blank\">reports</a> clinical results from its ongoing Phase 1/2a trial for GEN-009, the company\u2019s lead neoantigen vaccine candidate.</li>    <li>The results are as follows:</li><li>In the five patients, GEN-009 monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered.</li><li>GEN-009 has proven to be unique among neoantigen vaccines in its ability to elicit <em>ex vivo</em> CD8<sup>+</sup> T cell responses, which were observed for 47% of vaccine neoantigens. Inclusive of the results seen after <em>in vitro</em> stimulation, the CD8<sup>+</sup> T cell response frequency was 53%.</li><li>GEN-009 has been well tolerated to date, with no dose-limiting toxicities.</li><li>Shares are up <font color=\"green\">52%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3468515\" data-linked=\"Genocea up 52% premarket on positive GEN-009 data in cancer patients\" data-tweet=\"$GNCA - Genocea up 52% premarket on positive GEN-009 data in cancer patients https://seekingalpha.com/news/3468515-genocea-up-52-premarket-on-positive-genminus-009-data-in-cancer-patients?source=tweet\" data-url=\"https://seekingalpha.com/news/3468515-genocea-up-52-premarket-on-positive-genminus-009-data-in-cancer-patients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468509\" data-ts=\"1559564056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468509-annaly-capitalplus-1_7-after-1_5b-stock-buyback-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Annaly Capital +1.7% after $1.5B stock buyback program</a></h4><ul><li>Annaly Capital Management (NYSE:<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a>) <font color=\"green\">jumps 1.7%</font> in premarket trading its board <a href=\"https://seekingalpha.com/pr/17531433-annaly-capital-management-inc-announces-share-repurchase-program-1_5-billion\" target=\"_blank\">authorizes </a>the repurchase of up to $1.5B of its outstanding shares of common stock through the end of next year.</li><li>The buyback follows a <a href=\"https://seekingalpha.com/news/3457562-annaly-capital-minus-1_0-percent-plans-cut-q2-dividend-q1-core-eps-line\" target=\"_blank\">dividend cut</a> in May.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468509\" data-linked=\"Annaly Capital +1.7% after $1.5B stock buyback program\" data-tweet=\"$NLY - Annaly Capital +1.7% after $1.5B stock buyback program https://seekingalpha.com/news/3468509-annaly-capitalplus-1_7-after-1_5b-stock-buyback-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3468509-annaly-capitalplus-1_7-after-1_5b-stock-buyback-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468502\" data-ts=\"1559563036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468502-fedexminus-3-after-chinese-probe-launched\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx -3% after Chinese probe launched</a></h4><ul><li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) falls after the company <a href=\"https://seekingalpha.com/news/3468426-china-investigates-fedex-trade-war-provocation\" target=\"_blank\">lands</a> squarely in the middle of the U.S.-China trade dispute with Chinese regulators initiating a probe.</li><li>In a note published this morning, UBS says it's reasonable to anticipate pressure on FDX's business with a portion of its China outbound customers.</li><li>UBS has a Street-low price target of $136 on FedEx.</li><li>FDX <font color=\"red\">-2.88%</font> premarket to $150.01.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468502\" data-linked=\"FedEx -3% after Chinese probe launched\" data-tweet=\"$FDX - FedEx -3% after Chinese probe launched https://seekingalpha.com/news/3468502-fedexminus-3-after-chinese-probe-launched?source=tweet\" data-url=\"https://seekingalpha.com/news/3468502-fedexminus-3-after-chinese-probe-launched\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468499\" data-ts=\"1559562670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468499-william-hill-lower-after-report-on-failed-caesars-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">William Hill lower after report on failed Caesars merger</a></h4><ul><li>William Hill (<a href='https://seekingalpha.com/symbol/WIMHY' title='William Hill plc'>OTCPK:WIMHY</a>) and Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment Corporation'>CZR</a>) held <a href=\"https://www.thetimes.co.uk/\" target=\"_blank\">talks</a> last year about a merger, according to Sunday Times.</li><li>The deal reportedly fell apart due to the slow growth of Caesars' Las Vegas properties.</li><li>Shares of William Hill are <font color=\"red\">down 3.30%</font> in London trading after starting the day with an initial upward surge.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468499\" data-linked=\"William Hill lower after report on failed Caesars merger\" data-tweet=\"$WIMHY $CZR - William Hill lower after report on failed Caesars merger https://seekingalpha.com/news/3468499-william-hill-lower-after-report-on-failed-caesars-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3468499-william-hill-lower-after-report-on-failed-caesars-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468496\" data-ts=\"1559562173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468496-creeminus-14-on-valuation-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree -1,4% on valuation downgrade</a></h4><ul><li>BMO downgrades Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) from Outperform to Market Perform and keeps a $55 price target.</li><li>The firm cites a \"fairly balanced\" risk/reward at the current valuation.</li><li>But BMO thinks Cree is \"executing solidly on its transformation\" and sees wide bandgap semis as \"carving out a major presence in power semiconductors\" driven by 5G and electric vehicles.</li><li>Cree shares are <font color=\"red\">down 1.4%</font> pre-market to $54,38. Shares are down 20% from an April high but up more than 60% since an October low.</li></ul><div class=\"tiny-share-widget\" data-id=\"3468496\" data-linked=\"Cree -1,4% on valuation downgrade\" data-tweet=\"$CREE - Cree -1,4% on valuation downgrade https://seekingalpha.com/news/3468496-creeminus-14-on-valuation-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3468496-creeminus-14-on-valuation-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3468484\" data-ts=\"1559560655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEG\" target=\"_blank\">EYEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3468484-eyegate-up-59-premarket-on-fda-approval-to-initiate-prk-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EyeGate up 59% premarket on FDA approval to initiate PRK study</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17531281-eyegate-receives-approval-fda-initiate-prk-pivotal-study\" target=\"_blank\">approved</a> EyeGate Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals, Inc.'>EYEG</a>) to initiate its photorefractive keratectomy (\"PRK\") pivotal study.</li><li>EyeGate provided sufficient data to support initiation and FDA has requested to make some modifications to the patient informed consent document prior to enrollment.</li><li>The Company expects to begin enrollment this month. Topline results are expected by year-end and, assuming these are positive, EyeGate plans to submit the de novo application for commercialization shortly thereafter.</li><li>Shares are up <font color=\"green\">59%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3468484\" data-linked=\"EyeGate up 59% premarket on FDA approval to initiate PRK study\" data-tweet=\"$EYEG - EyeGate up 59% premarket on FDA approval to initiate PRK study https://seekingalpha.com/news/3468484-eyegate-up-59-premarket-on-fda-approval-to-initiate-prk-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3468484-eyegate-up-59-premarket-on-fda-approval-to-initiate-prk-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}